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ABSTRACT

COGNITIVE PERFORMANCE AS A FUNCTION OF RIGHTSIDED, LOW-FREQUENCY rTMS ADMINISTRATION USING CNS
VITAL SIGNS
Alexis J. Chappell
Old Dominion University, 2014
Director: Dr. Serina A. Neumann

Major Depressive Disorder (MDD) is a complex, widespread, and recurrent
psychiatric disorder. Although the majority of affected individuals respond adequately to
pharmacotherapy and/or psychotherapy, there persists a sub-population of affected
individuals who do not improve despite these interventions. Electric convulsive therapy
has been described in the research as the most efficacious options for treatment resistant
depression. However, due to the neurocognitive deficits associated with ECT, interest in
transcranial magnetic stimulation (TMS), a non-invasive approach that stimulates the
cerebral cortex, as an alternative to ECT has become a major research focus. The
efficacy of both high-frequency and low-frequency rTMS for depression have been well
documented although the impact on neurocognitive functioning is not completely
understood. Research to date has demonstrated neurocognitive improvement following
rTMS to the left dorsolateral prefrontal cortex only. Therefore, this study focused on the
neurocognitive changes associated with rTMS when administered to the right dorsolateral
prefrontal cortex and the supplementary motor area, utilizing data from the existing
EVMS registry for patients receiving TMS. Measures assessed depression (Beck
Depression Inventory-II), anxiety (Beck Anxiety Inventory), and neurocognitive
functioning (CNS-Vital Signs tests of executive function, cognitive flexibility, and

complex attention). A series of ANOVAs were conducted to examine: a) whether
statistically significant differences exist in neurocognitive scores following 2 and/or 6
weeks of rTMS treatment as compared to pre-treatment; and b) whether any significant
improvements in neurocognitive scores occur independent of a reduction in depression
and anxiety scores. As expected, results revealed statistically significant improvements
for all three neurocognitive domains across all three time points with the greatest
improvement taking place during the first two weeks of treatment with a stabilizing effect
thereafter. Results also revealed changes in depression and anxiety scores that were not
significantly correlated with Executive Functioning, Complex Attention, and Cognitive
Flexibility change scores. Therefore this study substantiates the use of right-sided, lowfrequency rTMS as a treatment alternative to ECT as it provides support for improved
cognitive functions that occur independent of mood improvements.
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CHAPTER 1
INTRODUCTION
The primary aim of the present study is to examine possible neurocognitive
improvements associated with the recommended clinical dose of repetitive Transcranial
Magnetic Stimulation (rTMS) in the treatment of resistant depression when administered
to the right dorsolateral prefrontal cortex and supplementary motor cortex. While
existing research supports enhanced cognitive functions following left-sided applications
of rTMS, right-sided applications remain unexplored. As the efficacy of rTMS for
treatment resistant depression continues to be established through recent and ongoing
research, the importance of elucidating its impact on the neurocognitive features
associated with Major Depressive Disorder (MDD) is paramount. This is particularly
true considering the established neurocognitive deficits resulting from the predecessor to
rTMS, electroconvulsive therapy (ECT). Therefore, the superiority of rTMS in the
treatment of refractory depression, not only demands equitable or increased efficacy as
compared to ECT, but also enhanced neuronal and neuropsychological changes resulting
from its application.
The remainder of this introduction includes a more thorough discussion of the
rationale for the study along with an overview of both low and high frequency
Transcranial Magnetic Stimulation (TMS). The epidemiology and treatment options for
depression and more specifically, treatment-resistant depression are also addressed. In
addition, an overview of the current structural and functional abnormalities and
neurocognitive deficits associated with depression and the impact of TMS on these
abnormalities will be included. These sections demonstrate the trend toward the use of
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TMS in the treatment of depression and provide justification for a study of this nature.
The final section will integrate the preceding sections and provide the final validation for
this study and the study hypotheses.
Rationale of the Current Study
Major Depressive Disorder (MDD) is not only widespread, but it also tends to be
recurrent. In fact, it is among the most prevalent of all psychiatric disorders. Up to 20%
of the general population will experience at least one episode of depression throughout
their lifetime and 80% of those affected will experience a relapse of symptoms. Despite
the advancements made possible through neuroimaging as well as through genetic and
molecular studies, depression remains a complex disorder characterized by vast
heterogeneity (Gotlib & Hamilton, 2008). What is more, there persists a considerable
sub-population of affected individuals who do not improve despite the use of
psychopharmacological and psychotherapeutic interventions. It is treatment-resistant
depression (TRD), with its debilitating nature and high economic cost, that has prompted
a shift from targeting synaptic transmission for treatment, which fails to completely
account for depressive symptomology, to a more comprehensive focus on neural circuitry
(O’Reardon, Peshek, Romero, & Cristancho, 2006).
Treatment-resistant depression, a term reserved for a lack of remission despite
antidepressant treatment in adequate doses (or intensity) and for a time sufficient for
response, has in large part, driven the research for Transcranial Magnetic Stimulation
(TMS) (Fava & Davidson, 1996). To date, electric convulsive therapy (ECT) has been
considered the most efficacious treatment for TRD. ECT is not without its drawbacks
however. Unlike rTMS, which is applied painlessly to awake patients, ECT utilizes

3

direct transcranial electrical currents, which requires patients to be anesthetized to ensure
comfort and to facilitate the administration of muscle relaxation. Aside from its invasive
nature and need for sedation, ECT has also been criticized for resulting in cognitive side
effects. Specifically, ECT has been shown to produce anterograde amnesia, retrograde
amnesia and subjective memory complaints (Schulze-Rauschenbach, Harms, Schlaepfer,
Maier, Falkai, & Wagner, 2005). For these reasons, interest in TMS, a non-invasive
approach that stimulates the cerebral cortex, as an alternative to ECT has become a major
research focus.
Transcranial magnetic stimulation is not the first use of magnets for healing. It is
however unique in its application. With the use of a pulsed electromagnetic field to
modulate neuronal activity in the cortex, TMS has been shown to produce antidepressant
actions. Some studies have even reported that the efficacy of TMS extends to the
maintenance treatment of depression (Wang, Xue, Chen, Zhang, Wnag, Yahong, Jingli,
Zhang, & Qingrong, 2013). The magnitude and breadth of potential of applicability for
rTMS for psychiatric and medical patients however is yet unknown. At present, the FDA
has approved rTMS for only a marginal sector of the patients. For its benefits to be more
fully known and for it to be approved more broadly by the FDA, all risks and benefits
must be scientifically demonstrated. Among these are any cognitive benefits and/or
impairments resulting from rTMS. This makes research into this inquiry and the
dissemination of findings to clinicians and patients alike, critical.
Like many psychiatric and medical conditions, depression is associated with
neurocognitive dysfunction. This has been confirmed not only through subjective reports
and neuropsychological testing, but with the advances of neuroimaging techniques as
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well. In fact, through these latter techniques, functional and structural abnormalities help
differentiate individuals with MDD from normals. They also confirm the need for
depression subtypes (e.g. symptom-based, aetiologically-based, time of onset, gender
based, and treatment-resistent) and have helped pave the path for specific and
individualized treatment options.
Overview of Transcranial Magnetic Stimulation (TMS)
The knowledge that nerves and muscles can be externally stimulated via applied
electrical currents has long since been established. In fact, initial experiments date back
to the 1790s and the work of Galvani and Volta. The term magnetic stimulation is a bit
misleading, however, as the magnetic field created during its administration does not
itself directly stimulate the tissue. Rather, the magnetic field pulse induces an electrical
field in the tissue, which causes an ionic current to flow. If in turn, the amplitude, spatial
characteristics, and duration of this induction cause depolarization of a nerve membrane,
then stimulation will occur (Barker & Freeston, 2007). The earliest application of rTMS
was used to explore susceptibility to seizure induction following stimulations of the
motor speed area of the dominant frontal lobe, the area thought to be the most
epileptogenic area of the brain. It was through these studies that the added ability of
rTMS over single-pulse TMS to produce sustained and spatially selective interruptions of
organized neural activity was discovered. Repetitive Transcranial Magnetic Stimulation
(rTMS) has lead also to the non-invasive mapping of cognitive and perceptual processes
in the human cortex (Wassermann, 1998).
The early 20th century marked the development of magnetic stimulation as a
clinical technique. The past 15 years however that have been pivotal in the discovery of
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the effectiveness of rTMS as a treatment for depressive disorders in particular. In 2008,
the United States approved rTMS for clinical use. Since that time, the interest in the
therapeutic effects of rTMS on depression among psychiatrists, neurologists, basic
scientists, and the public at large has surged (Fitzgerald & Daskalakis, 2012).
Treatment for depression, using rTMS involves a rapidly timed variable magnetic
field applied to a localized area of the cortex. The term repetitive refers to paced
administration of TMS to a single scalp site. Although only a restricted area receives
direct stimulation (with conventional equipment, TMS penetrates no further than 1.5-2cm
beneath the scalp), distal brain activity is impacted as well (Barker, 1991). It is through
the TMS coil that an electrical current is allowed to travel, without resistance, into the
brain. When the current passes through the coil, a magnetic field is produced and it is
this field, when provided above a certain threshold, that ignites electrical activity in the
underlying cortical neurons. Over time, with repeated firing, neurons will progressively
change their activity. High-frequency stimulation, the most researched TMS application,
for example, is known to produce an increase in local cortical excitability (Bohning,
Shastri, McConnell, Nahas, Lorberbaum, Roberts, Teneback, Vincent, & George, 1999).
The intensity of TMS is usually given as a percentage of the threshold intensity
for evoking motor evoked potentials (MEPs) of a certain amplitude in a specified fraction
of a series of consecutive trials in a hand muscle. Response thresholds to TMS vary
considerably. Therefore measures of intensity are formulated on the basis of biological
efficacy in the individual rather than the output of the stimulator itself. rTMS dosing is
determined on an individual bases with the use of an individual’s resting motor threshold
(RMT). This is established through the administration of individual TMS pulses to the
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motor cortex in order to identify the lowest intensity required to consistently induce a
motor response in a peripheral muscle, usually the abductor pollicis brevis, in the
contralateral hand. RMTs are lowest in the muscles of the hand due to the abundance of
the corticospinal projections that rely on their spinal motor neurons (Hanajima, Wang,
Nakatani-Enomoto, Hamada, Terao, Furubayashi, Okabe, Inomata-Terada, Yugeta,
Rothwell, & Ugawa, 2007). Antidepressant effects are observed from 90% to 120% of
the RMT, allowing for intensity reduction if treatment is not being well tolerated.
However, there does appear to be a relationship between intensity and efficacy, thus,
reductions should be limited (Loo, McFarquhar, & Mitchell, 2008).
TMS is most often administered at a high-frequency to the left dorsolateral
prefrontal cortex (DLPFC) at between 5 and 20 Hz. However, other stimulation sites are
now being targeted for research and clinical application. Two such sites are the right
prefrontal cortex and the supplementary motor area, using a low-frequency stimulation.
Low-frequency refers to stimulus rates of 1 Hz or less. Where high-frequency TMS
results in cortical excitability, low-frequency creates the opposite effect (Fitzgerald,
Fountain, & Daskalakis, 2006). Although it has not been as extensively researched, TMS
applied in low-frequencies to the right dorsolateral prefrontal cortex has also been found
to be efficacious when evaluated alone and equally efficacious when compared to the
left-sided approach. Currently, one meta-analysis exists on right-sided treatment and one
multisite sham controlled trial is being conducted, though no results are yet in print
(Schutter, 2009). Advantages of right-sided administration include, less demand on
equipment and thus fewer concerns about coil overheating, it tends to be better tolerated
and more comfortable, and it has a decreased risk of seizure induction. For these reasons,
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it can be used when high-frequency doses may exacerbate the existing anxiety
experienced by many depressed patients, when patients have a high RMT or a low
threshold of tolerance for high-frequency administration, or when there is evidenced
likelihood of seizure activity (Santiago-Rodriguez, Cardenas-Morales, Harmony,
Fernandez-Bouzas, Porras, Kattz, & Hernandez, 2008).
Regardless of the lateral site, TMS is typically provided five days a week for a
duration of two to nine weeks. There are studies currently exploring various treatmentscheduling options to optimize efficacy and efficiency, but the current recommendations
suggest that treatment should be provided five times per week unless the patient can only
attend three to four times per week, which may not undermine efficacy (Turnier, Bruno &
Pridmore, 2006). Regarding treatment duration, there is no clear maximum number of
treatments, but most studies support a minimum of six weeks. Subtle mood
improvements are typically expected in the second or third week, but others take longer.
If improvements are not noted after four weeks of treatment, a change in stimulation site
or intensity can be considered (Fitzgerald, Benitez, de Castella, Brown, Daskalakis,
Kulkarni, 2006).
Most studies evaluating the efficacy of TMS have involved patients who are not
on antidepressant medication. However, there are several trials that have included
patients on concurrent treatment and patients who began a pharmacotherapy trial at the
start of TMS treatment. The findings of these studies did not produce results suggestive
of benefit over sham. It has been speculated that this may be due to alterations in RMT
that interfere with treatment. For partial responders where medication is maintained
throughout TMS, it is recommended that RMT be assessed regularly and TMS dose be

8

adjusted accordingly (Herwig, Fallgatter, Hoppner, et al., 2007).
By its very nature, depression is a relapsing disorder; treatment responders to
TMS are no exception. However, the rate of relapse lends support to the efficacy of the
long-term benefits of TMS. For example, in their study including 99 patients who
received rTMS and were then tracked for 24 weeks, Janicak, Nahas, Lisanby et al.,
(2010) found that only 10 percent of participants relapsed. For patients who do see a
recurrence of symptoms, several studies have found results suggesting that most patients
will respond favorably if treated again using the same treatment parameters (Fitzgerald,
Benitez, de Castella, Brown, Daskalakis, & Kulkarni, 2006). Electroconvulsive therapy
(ECT), on the other hand, is associated with high rates of early relapse. In a metaanalysis of relapse rates in responders to an acute course of ECT administered for a major
depressive episode, Jelovac, Kolshus, and McLoughlin (2013) examined thirty-two
studies with up to 2 years’ duration of follow-up. Where pharmacotherapy was continued
following treatment, 51.1% of patients relapsed by 12 months following successful initial
treatment with ECT, with the majority (37.7%) relapsing within the first 6 months. The
6-month relapse rate was similar in patients treated with continuation ECT (37.2%). In
randomized controlled trials, they found that antidepressant medication halved the risk of
relapse compared with placebo in the first 6 months. Thus, despite the continuation of
ECT therapy, the risk of relapse within the first year following ECT is substantial, with
the period of greatest risk being the first 6 months. Maintenance of well-being following
successful ECT undoubtedly need to be improved.
Overall, TMS is well tolerated by patients. In fact, the discontinue rate is much
lower than what is typically observed in other treatments, particularly medication trials.

9

For example, in the two large multisite rTMS trials, the drop out rate in the active groups
were 12% and 10%; single site studies produced drop out rates averaging around 5%
(O’Reardon et al., 2007; George et al., 2010). In their meta-analysis examining dropout
rates in head-to-head medication trials for major depressive disorder, Machado, Iskedian,
Ruiz, and Einarson (2006) found drop out rates of SNRIs, SSRIs, and TCAs at 26.1%,
28.4%, and 35.7% respectively. Side effects are marginal compared with pharmacology
and include discomfort at the site of stimulation as well as headaches during and shortly
following treatment. The risk of these side effects is greatly reduced with guidelines now
stating that the procedure be prescribed by a physician and that stimulation parameters be
individually established. In rare instances, seizures have also been reported. However,
not only is the risk of seizure lower for rTMS as compared to ECT, safety studies of
rTMS have also shown inhibition of the motor cortex after low-frequency stimulation.
This finding suggests that such stimulation may actually be useful in suppressing the
development and spread of epileptogenic activity. Patients who do experience a seizure,
however, are generally not at an elevated risk of seizure than they were before (George,
Lisanby, Avery, et al., 2010).
Although the overall safety of rTMS is reassuring, there are a few
contraindications. For example, individuals with metal in their head, with the exception
of their mouth, are not good candidates for rTMS due to the potential for metallic
hardware being heated by the coil. Clinicians are also cautioned when considering rTMS
for patients with cardiac pacemakers and implanted medications pumps to consult with
the manufacturers of such devices. Compelling clinical reasons would also be necessary
to treat children and pregnant women with rTMS. Finally, tricyclic antidepressants,
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neuroleptic agents, and other drugs that lower the seizure threshold might be
contraindications for rTMS. In each of these circumstances, a conscientious risk-benefit
assessment must be conducted (Wasserman, 1998).
Epidemiology of Depression
According to the World Health Organization, affective disorders are the most
debilitating and the most significant contributors to the total burden of disease worldwide
(World Health Organization, 2001). The tremendous impact of depression is easily
explained by its high prevalence, its early onset, its recurrent nature, and the impaired
social and cognitive capabilities that result, thereby diminishing an individual’s ability to
adapt to life circumstances and to identify and obtain necessary resources (Miret, Ayuso,Mateos, Sanchez-Moreno, & Vieta, 2013). The burden of depression is not easily
resolved without efficient health systems and most importantly, available treatment
strategies.
Depression affects an estimated 350 million individuals worldwide. The rates of
depression swell during middle-to-late adolescence with gender differences emerging in
adulthood. In fact, twice as many women experience depression as men (Hankin and
Abramson, 2001). Within the United States, the lifetime prevalence is approximately
29.9% with a 12-month prevalence of about 8.6%. Not surprisingly, significant costs to
patients, their families, caregivers, employers, and insurance payers ensue resulting in an
estimated cost exceeding $80 billion each year in the United States alone. These costs, of
course are associated not only with health care but also with suicide mortality and lost
workplace productivity (Berry, Broglio, Bunker, Jayewardene, Olin, & Rush, 2013).
Of those affected by clinical depression, between 60 and 70 percent will respond
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to pharmacotherapy, dispensed at the maximum dose. An additional 10 to 20 percent will
improve following additional trials including first or second choice antidepressants. The
remaining 10 to 15 percent of patients will not respond to drug therapy and will be
classified as having treatment-resistant depression. This designation not only indicates
that the patient has not experienced a full remission, but has also not seen a 50 percent
reduction in depressive symptoms (Takahashi, Shirayama, Muneoka, Suzuki, Sato, &
Hashimoto, 2013). Not surprisingly, a distinguishing characteristic of this subgroup is
the common occurrence of suicidal thoughts, attempts, and in up to 10 percent of cases,
completed suicides, making the discovery of efficacious treatment options critical
(Ciprani, Girlanda, Agrimi, et al., 2013).
The primary treatment for TRD is electroconvulsive therapy (ECT). Due to the
potential side effects, associated stigma, and unfavorable risk-benefit ratio, many patients
with TRD will not elect to pursue ECT as a treatment option (Fava & Davidson, 1996).
The bulk of rTMS research has been conducted with this patient group with outcomes
suggesting that high-frequency stimulation applied to the DLPFC produced superior
antidepressant effects compared to sham in numerous meta-analyses, including over 1000
randomized subjects (Slotema, Blom, Hoek, Sommer, 2010).
The discussion of TRD would be incomplete without a review of
psychotherapeutic interventions. In fact, some have argued that a trial of cognitivebehavioral therapy by an experienced therapist should be performed before labeling an
episode of major depression as refractory or treatment resistant. In support of this
modification, Fava, Savron, Grandi, and Rafanelli (1997) examined nineteen patients
who failed to respond to at least two trials of antidepressant drugs of adequate dosages
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and duration who were then treated by cognitive-behavioral methods. Three of the
patients dropped out of therapy, but the remaining 16 experienced a significant decrease
in scores on the Clinical Interview for Depression after therapy. Twelve patients were
judged to be in remission at the end of the trial and only one of these patients was found
to have relapsed at a 2-year follow-up. Also in support of psychotherapy interventions
for TRD, Thase, Friedman, and Howland (2001) have suggested that the efficacy of
pharmacological interventions may be adversely affected by a poor therapeutic alliance,
low social support, life stress, or chronic adversity and cognitive or personality factors
such as neuroticism or pessimism. They review the literature suggesting that
interpersonal, cognitive, and behavioral forms of psychotherapy have shown to address
these complexities and should be considered as treatment options when pharmacotherapy
fails to produce adequate treatment response. Finally, in their meta-analysis examining
the treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy
combinations, Thase, Greenhouse, Frank, et al. (1997) found widespread support for
combined therapy in more severe, recurrent depressions. Taken together, it can be argued
that treatment resistant should apply only when a psychotherapeutic effort has been
made. Until then, it may be more appropriate to define depression as “drug refractory” or
“drug resistant”.
Neurophysiology/Pathophysiology of Depression
Major depressive disorder is a complex, heterogeneous diagnosis characterized by
a variety of neuroendocrine, neurochemical, neurophysiological, and neuromorphometric
abnormalities. Its etiology is related to the interaction of genetics, adverse events in
childhood, and ongoing and recent stress (Rot, Marije, Mathew, & Charney, 2009).
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Elucidating the interplay among neurotransmitters and the related structural, functional,
and psychosocial elements has been a major focus of research, especially with the advent
of neuroimaging (Gotlib & Hamilton, 2008).
Initial investigations into the neurobiology of MDD focused almost entirely on
the monoamine neurotransmitters serotonin (5-HT), norepinephrine (NE) and dopamine
(DA). Research into these neurotransmitters resulted in the monoamine hypothesis,
which has dominated the understanding of depression and driven pharmacological
approaches to its management. The hypothesis asserts that depression results from a
deficiency of monoamines at key sites in the brain (Van Praag, 2001). The hypothesis
however is not without its shortcomings. For example, it cannot account for why two to
three weeks of pharmacological interventions are required to resolve depressive
symptoms despite the fact that the monoamine levels targeted by these drugs show
increases in as few as one to two days. It also cannot explain the lack of antidepressant
effects by illicit drugs like cocaine and amphetamine, which enhance these same
neurotransmitters. Although most novel antidepressants reflect the claims of the
monoamine hypothesis, it is being increasingly undermined and new biological models
for understanding depression are now emerging. These new approaches have targeted
dysfunction of the hypothalamic-pituitary-axis, the hypothalamic-pituitary-thyroid,
second messenger pathways, calcium levels, and cytokines (Hindmarch, 2001). As the
knowledge of the brain and depression increases, the increased understanding of these
and other associated features will likely pave the path for novel antidepressants that
might be superior to those currently available.
As new biological approaches to understanding depression continue to evolve,
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molecular insights, and the monoamine hypothesis specifically, have been far from
abandoned. In fact, Rot, Marije, Mathew, and Charney (2009) have offered a revised
monoamine hypothesis suggesting that the role of serotonin should continue to be an
ongoing research emphasis, although a new perspective may be necessary. For example,
they assert that the low serotonin synthesis observed in depressed patients might not be
the cause of depression as traditionally thought but rather, the result of depression and
that a third variable, responsible for triggering depression, may actually be responsible
for the reduced synthesis.
The role of serotonin in depression is also not fully understood without
incorporating what is known about the genes that influence serotonin metabolism,
particularly during times of stress. It cannot be argued that stress is a common
precipitating factor for depression (Wurtman, 2005). Although no gene, or even a series
of genes, have been identified as a cause for depression, the serotonin transporter gene is
the most studied in MDD. It is of particular interest to scientists because it contains a
polymorphism, a gene variation that my increase the risk for depression, that gives rise to
two different alleles (long and short) that can occur in any combination. It is the short
allele that slows down the synthesis of the serotonin transporter, which in turn, inhibits
the speed that serotonin neurons can adapt to changes in their stimulation. Therefore, in
support of a gene-environment interaction, it appears that carriers of the short allele of the
serotonin transporter may be especially vulnerable to depression when faced with stress
(Caspi, Sugden, Moffitt, Taylor, Craig, Harrington, McClay, Mill, Martin, Braithwaite, &
Poulton, 2003). Other studies have built upon this finding and shown that serotonin is
not the only gene interacting with the environment to create a risk for depression. For
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example, Cicchett, Rogosch, Sturge-Apple (2007) examined child maltreatment and
polymorphisms of the serontonin transporter and monoamine oxidase A (MAOA) genes
in relation to depressive symptomatology. Findings did support a gene by environment
interactions but heightened depressive symptoms were found only among extensively
maltreated youth with low MAOA activity. Among comparably maltreated youth with
high MAOA activity, self-coping strategies related to lower symptoms. Sexual abuse and
the 5-HTT short/short genotype predicted higher depression, anxiety, and somatic
symptoms, but again, this interactions was further moderated by MAOA activity level.
Therefore, the interactive effects of multiple genes and psychosocial stress on the risk of
depression will require further research (Cicchett, Rogosch, Sturge-Apple, 2007).
Norepinephrine, another neurotransmitter driving the monoamine hypothesis, has
primarily been associated with the experience of stress whereby a threatening or novel
stimulus evokes an increase in NE activity. In the context of MDD, depleted NE levels in
response to prolonged or unresolved stress, dysregulate the mechanisms that would
typically allow a return to homeostasis following this threat response. This dysregulation
has been associated with cognitive symptoms such as hopelessness, helplessness, and
guilt. Antidepressants targeting the reuptake of NE specifically have demonstrated
comparable clinical efficacy to selective serotonin reuptake inhibitors (SSRIs) (Nemeroff,
Entsuah, Benattia, Demitract, Sloan, & Thase, 2008).
Like serotonin and norepinephrine, dopamine is another neurotransmitter that is
thought to play a critical role in the pathophysiology of MDD. Studies on it function in
depression have observed that environmental threats perceived by the amygdala raise the
level of dopamine in the prefrontal cortex as well as in the ventral striatum. As with
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norepinephrine functioning, inhibitory feedback allows a return to homeostasis following
a perceived threat. The possible lack of local inhibitory feedback in the striatal dopamine
system may help explain why depressed patients often attribute inappropriate salience to
even mildly negative stimuli (Dunlap & Nemeroff, 2007). Unlike serotonin and
norepinephrine, there are currently no antidepressants that directly impact DA
transmission. It has therefore been speculated that many patients with MDD might
experience unremitted or residual symptoms, an especially important consideration when
exploring treatment-resistant depression.
In addition to the molecular aspects of depression, the structural neurology of
MDD also continues to evolve and guide treatment options. In fact, there is an entire
sub-discipline of the biobehavioral sciences dedicated to clarifying the neural bases of
mood and emotion known as affective neuroscience (Davidson, Pizzagalli, Nitschke, &
Putnam, 2002). In response to the advanced neuroimaging techniques now available, key
regions of the brain implicated in MDD are now being more precisely identified.
Neuroscientists examining the emotional circuitry of depression have identified some
consistent findings that point to certain anatomical abnormalities. Such abnormalities
have been discovered in the limbic system, a complex of structures including the
amygdala, hippocampus, subgenual anterior cingulate cortex (ACC), and hypothalamicpituitary-adrenal axis. Cortical areas, namely the dorsolateral prefrontal cortex, also
appear to play a prominent role in depression, particularly with emotion regulation and
cognitive control (Davidson, Lewis, Alloy, Amaral, Bush, Cohen, Drevets, Farah, Kagan,
McClelland, Noel-Hoeksema, & Peterson, 2002).
Studies of the amygdala demonstrate its involvement in emotionally mediated
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attention, assigning emotional significance to stimuli and in remembering emotionally
significant events (Gotlib & Hamilton, 2008). Studies have shown that there is an inverse
relationship between amygdala volume and number of depressive episodes. Additionally,
in studies using positron emission tomography (PET), elevated amygdala activity,
cerebral blood flow (CBF), and metabolism, appear to be positively correlated with
depressive severity (e.g., Drevets, Bogers, & Raichle, 2002). Another consistent finding
suggests the presence of increased amygdala response to emotional stimuli. This is
particularly true in response to negatively valenced stimuli (e.g., Sheline, Barch,
Donnelly, Ollinger, Snyder, & Mintun, 2001). These patterns, while well documented,
do not occur in all patients with MDD. Rather, these trends appear to be more prevalent
in those who present with a high level of dispositional negative affect and anxiety
(Davidson, Lewis, Alloy, et al., 2002). In fact, it has been speculated that the increased
amygdalar activation in depression in general may also represent a possible biological
substrate for anxiety, which is often comorbid with depression (Davidson, Pizzagalli,
Nitschke, & Putnam, 2002).
In recent literature, the hippocampus, an area of the brain involved in episodic,
declarative, contextual, and spatial learning and memory, has also become implicated in
the expression of depression. Many forms of psychopathology, depression included,
involve difficulty in the context-regulation of affect. In other words, mood and anxiety
disorders can be characterized by the display of normative affective responses in
inappropriate contexts. An example would be sadness that may be appropriate in the
acute period following a loss but that persists for much longer. From this, some have
hypothesized that the tendency towards the inappropriate context-regulation of affect in
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depression may suggest hippocampal dysfunction. Recent morphometric studies have
indeed reported hippocampal atrophy in patients with MDD. Inconsistencies do exist
however and may relate to moderator variables that have not yet been identified or the
possibility that hippocampal atrophy may be a symptom and not a cause of MDD
(Davidson, Lewis, Alloy, et al., 2002).
Another limbic structure, the subgenual ACC is thought to mediate the subjective
aspects of emotions and emotional responses to stimuli. Decreases in activity and
volume for this brain structure are associated with depression (Drevets, Price, Simpson,
Todd, Reich, Vannier, & Raichle, 1997). One especially interesting finding, concerning
from the work of Siegle, Carter and Thase (2006), showed that individuals with
depression, who respond favorably to cognitive behavioral therapy have less subgenual
ACC response to affective words than do those who do not improve.
Other regions of the ACC have also been noted in patients with MDD. For
example, it has been postulated that the hypoactivation observed in dorsal regions of the
ACC in patients with depression might be associated with impaired modulation of
attention or executive functions and impaired monitoring of competition among various
response options. Further, the hypoactivation in ventral regions of the ACC may be
associated with blunted conscious experience of affect, hypoarousal, anhedonia, reduced
coping potential in situations characterized by uncertainty and conflict, and expectancy
violations between the environment and one’s affective state (Davidson, Pizzagalli,
Nitscheke, Putnam, 2002). Finally, one study again pointing to the heterogeneity of
depressive substrates and symptom expression found that a reduction of
anxiety/somatization symptoms was associated with decreased activation in the ventral
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ACC whereas improvements in psychomotor retardation symptoms were associated with
increased activation in the dorsal ACC (Brody, Saxena, Mandelkern, Fairbanks, Ho, &
Baxter, 2001).
Yet another consistent finding in the research on brain abnormalities in patients
with MDD involves over-activity of the hypothalamic-pituitary-adrenal (HPA) axis,
which is responsible for the neuroendocrine response to actual or perceived threats. In
fact, it is one of the most replicated biological findings in major depression (Davidson,
Lewis, Alloy, et al., 2002). There have been two hypotheses, which are not mutually
exclusive that been offered as pathophysiological explanations for the HPA over-activity
noted in depression. The first one points to the elevated levels of corticotropin-releasing
factor (CRF) common to depression, stating that these increased levels drive the HPA
axis into overdrive (Nemeroff, 1996). The second hypothesis suggests impaired negative
feedback at both the pituitary corticotrope and central glucocorticoid receptor levels
(Young, Hasket, Murphy-Weinburg, Watson, Akil, 1991).
Cortical structures have also become implicated in depression, namely the
dorsolateral prefrontal cortex (DLPFC). The left DLPFC is an area of the brain
responsible for maintaining the representation of goals and the means to achieve them.
The right DLPFC however, is hypothesized to be particularly important to the
maintenance of goals that require behavioral inhibition and withdrawal in situations that
involve strong alternative response options. Compared to healthy individuals, studies
have consistently demonstrated decreased activity during resting state (Mayberg, Lozano,
Voon, McNeely, Seminowicz, Hamani, Schwalb, & Kennedy, 2005), during relapse
(Bremner, Innis, Salomon, Staib, Ng, Miller, Bronen, Krystal, Duncan, Rich, Price,
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Malison, Dey, Soufer, & Charney, 1997), and in response to affective stimuli in the
DLPFC of depressed patients, predominantly on the left side (Hooley, Gruber, Scott,
Hillner, & Yurgelun-Todd, 2005). In studies using electroencephalographic (EEG),
asymmetric activation in anterior scalp regions of the DLPFC has been found showing
reduced left relative to right activation in depressed and dysphoric individuals (Bell,
Schwartz, Hardin, Baldwin, & Kline, 1998). Low levels of activity in the left DLPFC
would help to explain the tendency for persons with depression to ruminate, reflecting the
difficulties in cognitive control (e.g., Mayberg, Liotti, Brannan, McGinnis, Mahurin,
Jerabek, Silva Tekell, Martin, Lancaster, & Fox, 1999).
The asymmetrical findings in the DLPFC for patients with depression also reveal
some interesting discoveries specific to the right side. For example, Debener, Beauducel,
Nessler, Brocke, Heilmann, & Kayser, (2000) recently confirmed earlier findings of
greater relative right-sided frontal activation in depressed patients compared with
controls. Another related finding suggests that among women in particular, SSRI
treatment responders had significantly less relative right-sided activation compared with
non-responders. Considering the role of right prefrontal regions in components of
negative affect along with right posterior regions in arousal and anxiety, these findings
imply that those subjects with global right-activation who would be expected to have
symptoms of negative affect and anxious arousal are least likely to show improvements
with SSRI treatment.
The picture that emerges from the investigations into the neurobiological aspects
of depression is one that demonstrates certain trends, but not absolute consistency and
homogeneity. Although neuroimaging studies have unearthed trends in regional cerebral
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blood flow (CBF), volume, and glucose metabolism in the aforementioned areas, it is
important to note that disagreements do exist regarding the specific locations and
direction of these abnormalities. And, these structures are all interconnected in regionally
specific ways, and so, feedback is also bidirectional. It is therefore still too early to tell
which of the structural and/or functional abnormalities may be primary and which may be
secondary. Depression is above all else, a complex, disorder with multiple subtypes and
symptom profiles. Ongoing research will be necessary to more explicitly conceptualize
depression and the specific neural, functional, and structural abnormalities associated
with each. Parsing the heterogeneity of MDD on the basis of known brain circuitry is
proving to be a promising approach to subtyping that relies more on the objective
characterization of the specific affective deficits in patients with MDD and less on
descriptive nosology. This ambitious effort could lead to the characterization of different
endophenotypes that could then be used for genetic studies and more tailored treatment
approaches.
Neurocognitive Impairments in Depression
Along with pervasive mood symptoms and anhedonia, MDD is characterized by
disturbances in multiple domains including cognition. In fact, negative thought patterns,
including pervasive and rigid negative views of the self, the world, and the future are core
features of depression. Much like the neurocircuitry of depression however, the specific
cognitive aspects of depression are not yet fully understood. What is known, points to
two main types of cognitive abnormalities in MDD, cognitive biases and cognitive
deficits, which provide evidence for the potential neurobiological correlates of each
(Murrough, Iacoviello, Neumeister, Charney, Iosifescu, 2011).
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Cognitive biases, a particularly common facet of depression, involve directed
attention and memory towards negative themes in cognitive processing. Numerous
studies have demonstrated particular biases primarily related to perception and attention,
interpretation, and memory. Regarding perception, depressed individuals show
preferential perception and processing of information towards negative as compared to
positive or neutral information (Gotlib and Joorman, 2010). Similarly, it appears that
when interpreting information, depressed individuals tend to make stable, global, and
generally negative inferences for the causes and consequences of life events (Fresco,
Heimberg, Abramowitz, & Bertram, 2006). Finally, as it pertains to memory, studies
have shown that depressed individuals are less able to expel irrelevant negative
information from working memory than their non-depressed counterparts. They also
appear to be more impaired at identifying positive content in the context of
representations competing for resources in working memory (Levens & Gotlib, 2009).
Despite these findings, and the gains made in characterizing the negative biases of
depression, their specific role is far from clear. And like many other factors associated
with MDD, the question regarding which is the predecessor, negative biases or depressed
mood, remains unanswered.
Coupled with the research gains made in documenting the aspects of negative
processing bias in depression, research has also focused on the deficits in cognitive
functioning unrelated to emotional processing. Much like the expression of cognitive
biases, the domains most commonly documented in the literature are attention, executive
functioning, and memory. Deficits in these domains are consistently documented and
similar in both vegetative and depressive subtypes (Herrera-Guzman, I., Gudayol-Ferre,
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E., Jarne-Esparcia, A, et al, 2009). It is believed that the deficits noted across these two
groups are due to the reduced metabolic activity within dorsal regions of the prefrontal
cortex in combination with the elevated limbic activity in MDD (Murrough, Iacoviell,
Neumeister, Charney, Iosifescu, 2011).
Although they are not mutually exclusive and the tasks used to measure cognitive
domains have considerable overlap, there is enough distinction to discuss them
separately. Executive function, which is known to originate in the anterior regions of the
brain, encompasses judgment, planning, abstract thinking, metacognition, cognitive
flexibility, inhibition, verbal fluency, initiative, and the ability to direct behavior in a
goal-directed fashion (Levin, Heller, Mohanty, Herrington, & Miller, 2007).
Impairments across these facets of executive function have been demonstrated in
individuals with depression. Despite this, a clear pattern of impairment with regard to
subtype of depression, severity, or medication status has not been identified. This might
be due to the multiple strategies that can be used to perform these tasks and the
comorbidity of depression and anxiety (Rogers, Kasai, Koji, Fududa, Iwanami,
Nakagome, Fukuda, & Kato, 2004).
The neural physiology of depression helps bolster what is known about the
executive functions common in MDD. The majority of studies have demonstrated that
elevated activity in a brain region is linked to increased performance on tasks specialized
to that region (Heller, Kitschke, Etienne, & Miller, 1997). As already addressed, there is
an asymmetry of the frontal lobe with decreased activity in the left dorsolateral prefrontal
cortex. On a broad level, the left prefrontal cortex appears to be associated with many of
the deficits seen in depression including, but not limited to, the capacity to construct

24

meaning and generate inferences that extend beyond the information presented,
strategizing, initiation, and self-cuing (Banich, 2004). The distinct functions associated
with the right prefrontal cortex are less understood. However, preliminary neuroimaging
has suggested that inhibitory control, the suppression of unwanted memories, and
involvement in the threat-response network are specialized functions of this region.
There are a limited number of studies that have specifically investigated the relationship
between the hyperactivity of the right dorsolateral prefrontal cortex and the regionally
specialized tasks in MDD. It has been hypothesized however, that such studies will
display deficits that correspond with the elevated activity and the specialized tasks
associated with this region (Nitschke, Heller, & Miller, 2000).
Along with impairments in executive function, there are a number of memory
deficits that have been demonstrated in patients with depression including problems with
autobiographical remembering, episodic memory recall, and working memory (Levin,
Heller, Mohanty, Herrington, & Miller, 2007). The association between depression and
memory has been identified as quite stable in a meta-analysis examining 147 recall and
recognition studies in clinically depressed and non-depressed samples. In this same
review, two particular findings emerged: deficits with explicit memory tasks were more
pronounced than implicit tasks and patients with MDD have a propensity to remember
negative material better than positive material (Burt, Zembar, & Niederehe, 1995).
Although memory deficits are well documented in persons with depression, the
reasons for this trend in depression are a bit less clear. One hypothesis argues that the
deficits in executive function may be partly responsible. Heller and Nitschke (1997)
proposed this possibility in response to the finding that depression limits the ability to
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initiate the cognitive strategies that enhance an individual’s ability to process and
remember information. Another theory has to do with attentional control strategies,
which are underutilized in person’s with depression. In studies where these strategies are
specifically treated through focusing and relevance strategies, memory deficits in
depression have been observed (Hertel, 1994). Finally, abilities to efficiently encode
information and lack of engagement with effortful memory strategies might help to
explain these particular cognitive deficits.
The memory deficits inherent to MDD have also prompted researchers to begin
investigating the hippocampal abnormalities associated with the disorder. These studies
have focused on hippocampal volume however and have not yet targeted how
hippocampal function is specifically related to cognitive ability. It is expected however
that research exploring the intersection of the affective and cognitive aspects of
subcortical regions will soon ensue (Levin, Heller, Mohanty, Herrington, & Miller,
2007).
Along with deficits in executive function and memory, impaired attention is
another cardinal feature of depression. In fact, one of the cognitive criteria for the
diagnosis of depression in the DSM-IV-TR is decreased concentration. Not only is
attention a prominent feature of depressive episodes, but problems with sustained
attention have also been evidenced as an ongoing problem even during periods of
symptom remission (Weiland-Fiedler, Erickson, Waldeck, Luckenbaugh, Pike, Bonne,
Charney, & Neumeister, 2004).
As with memory, it appears that many of the attentional deficits observed in
depression may result from impairments in executive function. Individuals with MDD

26

often show an impaired ability to suppress external and internal distractors, which in turn,
leads to an insufficient allocation of resources. Evidence for this difficulty in persons
with depression stems from performance on attentional tasks, which require distractor
inhibition, such as the color-word Stroop task (Levin, Heller, Mohanty, Herrington, &
Miller, 2007). Deficits in attentional processing in depression have also been
demonstrated with event-related brain potential (ERP) studies. The results from such
studies suggest that difficulties with attention are not merely the result of diminished
motivation (Fernandes et al., 1999; Keller et al., 1999).
The cognitive performance associated with depression is yet another reminder of
its diverse etiologies and manifestations. Despite the vast number of genetic and
environmental configurations, depression does appear to affect similar brain regions and
the functions associated with these cortical and subcortical areas. Therefore, while the
discovery of consistent patterns of relationships among specific cognitive impairments
and specific brain region activity is not yet clear, affective neuroscience is proving that
continued research efforts are paying off. With continued exploration into the cognitive
deficits associated with depression and its various subtypes, the search for respective
treatment methods that can ameliorate depression becomes more and more promising.
Effect of TMS on Depression Mechanisms
The efficacy of both high-frequency (HF) and low-frequency (LF) rTMS for
depression have been well documented although the underlying mechanisms are not yet
fully understood. The bulk of existing studies have focused on HF application to the left
dorsolateral prefrontal cortex (DLPFC). This type of stimulation has been shown to
produce greater antidepressant effects than sham in multiple meta-analyses, including
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more than 1000 randomized subjects (Schutter, 2009; Slotema, Blom, Hoek, et al., 2010).
Like HF applications, LF rTMS applied to the right DLPFC and supplemental
motor area has also been evaluated in a number of trials with promising results. In fact, it
has been found to be efficacious when evaluated alone and in all comparative trials, it has
been shown to share equal antidepressant effects with HF, left-sided treatments
(Fitzgerald & Daskalakis, 2012). At present, one meta-analysis exists confirming the
efficacy of right-sided treatments for depression (Schutter, 2010).
The bulk of findings related to the antidepressant mechanisms of rTMS stem from
animal studies. Such studies have demonstrated effects of rTMS on dopaminergic
neurotransmission, a neural substrate of depression previously discussed. Elevated
dopamine concentrations have been found in multiple brain regions following both HF
and LF treatments. Coupled with increased dopamine, these same studies observed
increased extracellular glutamate in the same regions (Padberg & George, 2009). Despite
this and other studies that have found an effect of rTMS on the neurotransmitter systems
involved in the pathophysiology of MDD, the comparison to prefrontal rTMS is a bit
controversial in humans given the functional anatomical differences in men and rodents.
In a recent study however, Strafella, Paus, Barrett, and Dagher (2001), did observe an
induction of dopamine release in the caudate nucleus of healthy volunteers following
rTMS.
As discussed earlier, two consistent findings reported in the MDD neuroimaging
literature are the metabolic hypoactivity in the left DLPFC and hyperactivity in the right
DLPFC, areas, which are interconnected to the brain circuits involved in cognitive and
emotion regulation (Schutter, 2009, Juckel et al., 1999). Thus, it has been proposed that
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stimulating neuronal activity in these brain region will, in turn, exert indirect effects on
underlying interconnected brain regions and will result in antidepressant effects (Juckel et
al., 1999). The DLPFC is anatomically situated on the surface of the cortex, making it a
highly conductive brain region for exteriorly applied stimulation (the TMS coil is able to
emit magnetic field pulses through the cranium that remain sufficiently strong for
approximately 2-3 centimeters deep). Again, TMS produces an electrical field that
induces neuronal depolarization that then initiates an action potential. It is this action
potential that ignites an excitation of neuronal activity. “Repetitive” TMS is utilized to
achieve sustained modulatory effects. It is this rationale that has been proposed as the
explanation for the documented antidepressant resulting from rTMS treatment. However,
an explanation of the exact mechanism of action driving these effects has not yet been
completely determined.
Although cerebral blood flow (CBF) abnormalities are a consistent finding in the
MDD research, there appears to be an asymmetry in the DLPFC, with reduced flow on
the left and increased flow on the right. rTMS addresses this heterogeneity as highfrequency application enhances cerebral blood flow to the left and low-frequency
application inhibits cerebral blood flow on the right. In fact, in their study investigating
changes in blood flow following low-frequency right prefrontal stimulation (LFRS), Kito,
Hasegawa, & Koga (2011), found that the therapeutic efficacy of LFRS was correlated
with decreases in CBF not only in the right prefrontal cortex, but also in the bilateral
orbitofrontal cortex, right subgenual cingulate cortex, right putamen, and right anterior
insula. ECT on the other hand has not been shown to improve upon the cerebral blood
flow abnormalities associated with MDD. For example, Nobler, Sackeim, Prohovnik,
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Moeller, Mukherjee, Schnur, Prudic, and Devanand (1994) found that global and regional
deficits in cerebral blood flow and glucose metabolism were not reversed by successful
treatment with ECT. In fact, in their study, ECT resulted in additional perfusion
reductions.
Although the antidepressant efficacy of rTMS for MDD has been repeatedly
demonstrated, the neuromechanisms implicated in this effect are not fully understood and
thus, more research is required. However, for now, there is strong research support for
the emotional and behavioral consequences associated with its application in patients
with MDD and what is known about the mechanisms of action for this does parallel the
known neural substrates of depression.
TMS and Neurocognitive Changes in Depression
The negative impacts on cognitive performance have been the major criticism of
the treatment methods typically used for depression. As already discussed, ECT has been
associated with both subjective and objective memory impairments. And, even when
successfully treated with modern antidepressants, patients tend to be better cognitively
than untreated patients, but they do not perform better than healthy comparison subjects
(Gualtier, Johnson, & Benedict, 2006). What makes rTMS so appealing, in addition to its
proven efficacy for treatment resistant depression, are the number of studies that show
that in modulating cortical networks, enhancements in cognitive performance result.
Cognitive enhancement has been defined as any augmentation of the core
information processing systems in the brain, including mechanisms underlying
perception, attention, conceptualization, memory, reasoning, and motor performance
(Luber & Lisanby, 2013). Beginning with healthy individuals, studies investigating the
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neurocognitive consequences of TMS and rTMS focused on domains including attention,
memory, executive functioning, and motor processing. Across these studies, no adverse
neurocognitive effects were observed and to the contrary, a trend towards enhanced
functioning emerged (Bridgers and Delancy, 1998; Hufnagel et al., 1993; Pascual-Leone
et al., 1993; Wasserman, 1998; Jahanshahi et al., 1997).
Studies evaluating the neurocognitive effects of TMS in the treatment of
depression have produced similar results, despite varying stimulation parameters (Little
et al., 2000; Speer et al., 2001; Avery et al., 1999; Padberg et al., 1999; Triggs et al.,
1999; Loo et al., 2001). This is especially promising as the use of rTMS in depressed
populations typically involves longer exposure and more aggressive stimulation
parameters and because as compared to healthy volunteers, patients with depression
typically present with state-dependent cognitive dysfunction (Martis et al., 2003). As the
evidence mounts concerning the lack of adverse effects resulting from rTMS treatment,
the precise neurocognitive changes remain unclear and require additional systematic
study. Results of previous research in this area are discussed below.
In their study on the cognitive effects of a 10-day trail of both low and highfrequency rTMS administered to the left PFC, Little et al. (2000) looked specifically at
verbal learning, memory and fluency abilities. Results suggested no adverse cognitive
effects and in fact, demonstrated gains in list recall after one week as compared to
baseline. Using similar parameters over a 2-week trail, Speer et al. (2001) also found no
decrease in scores and a “trend” suggesting improvements in verbal fluency. In a study
utilizing 5 session of TMS administered to older adults, Moser et al. (2002) found
significant improvements in executive functioning abilities (Trail Making Test-B). And
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after only 5 days of rTMS, Padberg et al. (1999) demonstrated verbal memory
improvements using both high and low frequency rTMS to the left PFC. Using the same
stimulation site and high frequency (20Hz) rTMS, Triggs et al. (1999) found elevated
scores on test of executive functioning and attention after 10 days. Finally, in a study
using high frequency to the left PFC, Bayan (2013) found significant improvements in
executive function, complex attention, and cognitive flexibility following 30 days of
rTMS.
In one particularly interesting studying comparing the neurocognitive effects of
unilateral ECT and rTMS in 30 treatment-resistant depression, Schulze-Rauschenbach et
al. (2005), produced results favoring rTMS. Specifically, the rTMS group demonstrated
improved cognitive performance and subjective memory complaints while the ECT group
displayed deficits in anterograde and retrograde memory as well as ongoing subjective
memory complaints. The incorporation of a healthy volunteer control group helped to
minimize the potential for practice effects in this study.
It seems as though the potential adverse effects of rTMS on neurocognitive
function are benign, and that there may even be some neurocognitive improvement
resulting from this treatment for MDD, at least for left-sided treatments. Nevertheless, it
is vital to continue investigating how different and potentially more effective stimulation
parameters, including stimulation site, may affect the occurrence of cognitive side effects.
After considering left-sided treatments from 6 open and 24 controlled studies from 1999
to 2009, Guse, Faliki, & Wobrock (2010) concluded that certain sub-domains of
executive functioning seem to exhibit the greatest improvement including working
memory, cognitive flexibility, and verbal fluency/retrieval. However, standardization of
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treatment parameters across the studies reviewing was lacking, possibly explaining the
variability across neurocognitive domain improvement in the studies reviewed.
Furthermore, the vast majority of studies using rTMS have yet to evaluate the impact of
neurocognitive change following right-sided applications, thereby warranting further
investigation.
Study Rationale Conclusions and Hypotheses
Depression is a prevalent, disabling, and often, chronic psychiatric condition.
More than 30% of those affected will not experience remission in response to traditional
treatments, namely pharmacology. This treatment-resistant cohort has historically been
left with limited treatment options. For this reason, different brain stimulation methods
have received considerable research attention throughout recent decades. The oldest of
these methods, electroconvulsive therapy, is considered an effective antidepressant for
the acute intervention of treatment-resistant depression. It is however, invasive, noteasily tolerated, and has been linked to significant cognitive side effects. rTMS is now
emerging as a treatment modality with equal efficacy for treatment resistant depression.
Unlike ECT however, rTMS is safe, non-invasive, and has been linked with
neurocognitive improvements.
An emerging theme from the literature on the neurobiological aspects of
depression is the unresolved question regarding the possibility that the cognitive aspects
of the disorder represent a separate dimension of the illness rather than being attributable
to the core mood symptoms alone. Providing support for their distinctness, are the
longitudinal studies that illustrate a subset of MDD subjects whose cognitive deficits
persist, especially in the areas of sustained attention, verbal learning and memory, and
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executive functioning, even when depressive symptoms have improved (Fava, Graves,
Benazzi, Scalia, Iosifescu, Alpert, & Papakostas, 2006). Therefore, it is essential to
continue the quest to delineate the aspects of depression, particularly the cognitive
dysfunction that may result in poor psychosocial functioning, and may persist beyond
certain symptom remission. Clarity in this regard may justify specific treatment
strategies aimed at the cognitive and functional deficits in these patients (Murrough et al.,
2011). rTMS is particularly promising as it’s electromagnetic stimulation of neurons
capitalizes on neuroplasticity to induce lasting neuronal change within multiple brain
regions. Thus, rTMS carries not only the promise of addressing the neural substrates
responsible for the affective experience of depression, but the possibility of targeting the
neurobiological basis of the neurocognitive deficits as well. Preliminary studies have
begun to provide evidence for this latter possibility, though treatment parameters are
varied, with many studies utilizing stimulation parameters below what has been
recommended and have assessed neuropsychological performance with paper and pencil
tests alone. In this study, an entire course of treatment was completed using the
recommended dose of rTMS (35 sessions of 1,200 pulses @ 1Hz, 110% to the RDLPFC
and 1,200 pulses @ 1 Hz, 100% to the SMA). The stimulations were delivered in 1second pulses each and neuropsychological testing utilized computerized administration,
enhancing standardization. This study was also one of the first to investigate the
neurocognitive changes associated rTMS administration to the RDLPFC and SMA.
Research Questions
1. Are there statistically significant differences in neurocognitive scores following 2
and/or 6 weeks of rTMS treatment as compared to pre-treatment?
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2. If significant improvements in neurocognitive scores are found, do these
improvements occur independent of a reduction in depression scores?
Discussion of Possible Outcomes
This study aimed to assess the impact of approximately 35 sessions of lowfrequency rTMS on neurocognitive functioning in the treatment of treatment-resistant
depression. The current study hypothesized that when low-frequency rTMS was applied
to the right DLPFC as well as to the supplementary motor area, significant improvements
in executive functioning, complex attention, and cognitive flexibility scores, as measured
by CNS Vital Signs (computer-based test battery), from pre-treatment to post-treatment
would be observed. Furthermore, it was hypothesized that improvements in
neurocognitive scores would be evidenced after the initial 2 weeks of treatment with
continued improvements in scores at post-treatment (Hypothesis 1A). It was believed,
based on the findings of previous studies, that improvements would take place
independent of improvements in clinical depression and anxiety scores, as measured by
the BDI-II and the BAI (Hypothesis 1B). Stated differently, neurocognitive score
improvements would be evidenced independent of mood improvement, suggesting
mechanisms of change in cognition via neuronal activation in the DLPFC versus
improvement in mood alone. If these hypotheses are upheld, it will further validate
rTMS as a non-invasive and effective treatment alternative to ECT that offers
neurocognitive benefit versus neurocognitive impairment.
In the event that these hypotheses were not upheld, several explanations could
have been applicable, beginning with methodological limitations. The very limitations of
subject enrollment itself in TMS studies and patients in TMS treatment programs (e.g.,

35

financial, time commitment, unfamiliarity with the treatment, etc.), could have impacted
the results, leading to non-significant neurocognitive pre- to post-treatment score
improvements or changes due to small sample size and low statistical power. These same
factors may have also caused sample bias and limited the study sample demographic
(e.g., higher socioeconomic status, higher education levels, older in age). If however the
subjects had varied vastly in age, discomfort with the use of computers for the older
subjects may have led to confounded results. Another potential restriction was the
computer-based test battery used in the study, CNS Vital Signs, which may have lacked
adequate sensitivity to assess the construct of interest (i.e., neurocognitive functioning) in
a clinical population over time. Improvements in neurocognition might also have been
explained by a correlation that exists between improvement in mood scores and
improvement in neurocognition. In other words, if results had revealed that
neurocognitive improvement did not exist independent of mood changes, then it could
have been expected that a lack of significant change in mood scores would illicit no
significant change in neurocognition. A lack of controlled circumstances for subjects
undergoing rTMS treatment may have also confounded the results. Such circumstances
included differences in supplemental treatments for depression (e.g., medications,
psychotherapy), adherence to the rTMS treatment schedule, severity of depression at
baseline, and severity of neurocognitive impairment at baseline.
It was also possible that if non-significant findings were revealed, it may have
been due in part to the stimulation parameters themselves. In the bulk of studies
illustrating significant improvement in cognitive functions, a left-sided treatment has
been used. This study was one of the first to explore cognitive change in response to
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right-sided protocols, which involve two stimulation sites, the right dorsolateral
prefrontal cortex (RDLPFC) and the supplementary motor area (SMA). As compared to
left-sided treatments which typically involve 3,000 pulses administered at 120% of the
established motor threshold to a single site and a stimulation time of 4 seconds given at
intervals of 26 seconds, this study included the following: 1,200 pulses @ 1Hz, 110% of
motor threshold (MT) administered to RDLPFC and 1,200 pulses @ 1Hz, 100% MT
administered to the SMA.
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CHAPTER II
METHODS
Participants
Data were derived from a larger study led by Serina Neumann, PhD., Associate
Professor of Psychiatry and Behavioral Sciences at Eastern Virginia Medial School
(EVMS). The study protocol was approved by the Institutional Review Board of EVMS
on August 24, 2010 (IRB#: 10-07-FB-0135-EVMS). The purpose of this larger study is
to establish a registry, or data bank, with information routinely employed in clinical
practice on patients receiving TMS for the treatment of cognitive, emotional, and
behavioral disorders (e.g. Major Depressive Disorder, Obsessive Compulsive Disorder,
and Post Traumatic Stress Disorder) in humans. These data will serve to elucidate factors
that may optimize or hinder the effectiveness of TMS in the treatment of these disorders.
As a part of the broader treatment trial, all patients underwent neurocognitive testing via
CNS Vital Signs to monitor neurocognitive changes associated with TMS treatment.
rTMS and TMS treatment eligibility inclusion criteria for participants in the current study
were as follows: 1) between the ages of 18 and 89; 2)DSM-IV diagnosis of MDD
(determined by symptom review in the clinical interview and Beck Depression Inventory
(BDI-II) score of ≥ 16); and 3) failed at least one antidepressant medication trail in the
past at or above the minimal effective dose and duration in the current episode. TMS
treatment eligibility exclusion criteria for participants in the current study were as
follows: 1) currently suicidal; 2) currently pregnant (as determined via blood test); 3)
seizure risk: history of seizure disorder, disease or injury that increases seizure risk (e.g.
serious heart disease, increased intracranial pressure due to acute large infection or
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trauma), family history of epilepsy, currently on medications that might increase seizure
risk; 4) implanted electrodes or devices in the body or head; 5) skull defects; 6) tinnitus;
7) psychotic features; 8) currently taking Wellbutrin and disinclined to discontinue; and
9) any other contraindications for rTMS. Along with the clinical interview, medical
records and clinical measures were reviewed to determine the above inclusion and
exclusion criteria.
Procedures
Recruitment. TMS patients were recruited via referral from various clinicians in
the surrounding community as well as clinicians within the Eastern Virginia Medical
School (EVMS) Department of Psychiatry group. Each referred patient initially
underwent an initial intake with the study coordinator to screen for any obvious
contraindications and diagnostic appropriateness. If patients were determined to be
eligible, they then underwent two clinical evaluations. A psychiatrist provided an initial
interview aimed at evaluating treatment suitability, obtained a brief psychiatric history,
and gathered a thorough psychiatric medication history. A licensed psychologist then
conducted the second evaluation obtaining a more in-depth psychiatric history and
assessment of symptoms. Once cleared (i.e., all eligibility criteria outlined in
Participants section met) and deemed medically appropriate, the frequency and duration
of treatment for each individual patient was determined by both clinicians and prescribed
by a board-certified psychiatrist.
Setting. TMS treatment and assessments take place at EVMS, Psychiatry and
Behavioral Sciences.

39

Administration of treatment and assessments. Once they were deemed eligible
via clinical evaluations, treatment parameters for individual participants were prescribed
by a board-certified psychiatrist. For depression, treatment was prescribed five days per
week for 6 weeks (approximately 40 minutes per session) and 3 weeks of subsequent
tapering (e.g., 3 TMS sessions during the 7rd week, 2 during the 8th week, and 1 during
the 9th week).
Prior to beginning TMS treatment, clinical and registry consents were discussed
and signed. Consent forms that outlined the registry study and TMS treatment purpose,
procedures, risks, and benefit, were provided to each patient who was then asked to
indicate their willingness to participate. Thereafter, patients underwent neurocognitive
and psychological testing in order to ascertain baseline values. For the purposes of this
study, the BDI-II and the BAI were the only psychological assessment measures
examined. Neurocognitive functioning was assessed using CNS Vital Signs, a computerbased neurocognitive assessment battery. Neurocognitive and psychological assessments
took place at 3 different time points throughout the trial (baseline, 2 weeks after starting
treatment, and at the end of treatment), with each neurocognitive testing session taking
approximately 25 to 30 minutes.
Prior to the initial TMS treatment session, the patient’s resting motor threshold
was established (RMT). This ensured precision of stimulation intensity as motor
threshold can vary depending on factors such as age, gender, and cortical excitability
(Lisanby, S. H. et al., 2002; Wassermann, E. M., 1998). RMTs were determined by
applying a single magnetic pulse over the right motor cortex region, which stimulates a
slight twitch in the contralateral hand. Magnetic pulses were applied in this fashion until
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a slight twitch in the contralateral thumb was achieved. The intensity of stimulation was
set at a maximum of 110% for the RDLPFC and 100 % for the SMA. Magnetic field
intensity for each patient’s resting motor threshold was calculated by the NeuroStar
software. The coordinates of the resting motor threshold (RMT) and stimulation site, as
well as the chair positioning parameters, were recorded using a positioning system to
ensure reliable repositioning upon subsequent treatment sessions. Once stimulation
intensity was determined, the exact site of stimulation was located and the coil moved
accordingly. The two stimulation sites for this study were the right DLPFC, which is
located approximately 5 cm anterior to the pre-central gyrus or motor strip, and the
supplementary motor cortex which is located approximately 2 cm anterior to the precentral gyrus or motor strip. Each treatment session consisted of 1,200 pulses @ 1Hz,
110% to the RDLPFC and 1,200 pulses @ 1 Hz, 100% to the SMA. The stimulations
were delivered in 1-second pulses each.
Materials
Beck Depression Inventory-II (BDI-II). For this study depression was assessed
using the BDI-II (Beck, Steer, & Brown, 1996). The Beck Depression Inventory-II is the
most recent revision of a test with more than 35 years of nearly universal use. It was
released in 1996 with the purpose of detecting the presence of depression in normal
populations as well as the severity of depression in diagnosed patients for both adults and
adolescents over the age of 13 (Arbisi, 1996). The measure consists of 21 items, each
item made up of 4 statements organized in increasing severity rated on a 0-3 scale. The
summary scores range from 0 to 63, with higher scores indicated higher levels of
depression over the past week. During its development, considerable attention was given
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to its ability to assess symptoms that correspond to the criteria listed in the DSM-IV for
diagnosing depressive disorders. The psychometric properties of the BDI-II are quite
good. Regarding internal consistency, coefficient alpha for the normative samples were
as follows: outpatient sample = .92; college sample = .93.

This was a notable

improvement over the BDI-IA, which had an alpha coefficient of .83. On a related note,
the test-retest reliability has been reported in the BDI-II at .93 (p < .001) (Beck, Steer, &
Brown, 1996).
Beck Anxiety Inventory (BAI). For this study, anxiety was assessed using the
BAI, which was released in 1988 by Beck, Epstein, Brown, and Steer. It was designed as
a measure of anxiety, one of the most common complaints by patients seeking mental
health treatment. It is a 21-item self-report measure that was created to assess solely
anxiety, and not depression. The BAI was developed using questions from the following
three measures, all of which were authored or coauthored by Beck: the Anxiety Check
List (ACL), the Physician’s Desk Reference Check List (PDR), and the Situational
Anxiety Checklist (SAC). The 21 questions on the BAI examined the following anxiety
symptoms: numbness/tingling, hot sensations, wobbly legs, inability to relax, fear of the
worst, dizziness/lightheadedness, heart pounding, unsteadiness, terrified feelings,
nervousness, feeling of choking, trembling hands, shakiness, fear of losing control,
breathing difficulty, fear of dying, feeling scared, indigestion or stomach discomfort,
feeling faint, flushed face, and sweating (due to something other than heat) (Beck &
Steer, 1987). In his Review of the Beck Anxiety Inventory (2010), Dowd praised the
measure for having excellent internal consistency reliability coefficients (ranges .84 to
.95). Test-retest reliability over one week showed a coefficient of .75 and appears to be
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stable over a one-month period (Beck, Epstein, Brown, & Steer, 1988). Regarding
content validity, the BAI was created with the DSM-III-R symptom criteria as a
guideline; mostly notable symptoms of Generalized Anxiety Disorder and Panic Disorder
were used in this measure. Concurrent validity correlation coefficients ranged from .51
to .58 across multiple studies, so Beck and Steer concluded that the correlational
magnitudes “demonstrate that the BAI is not only significantly but also substantially
related to other accepted measures of both self-reported and clinically rated anxiety”
(Beck & Steer, 1987).
CNS Vital Signs. CNS Vital Signs, a 30-minute, self-administered, computerbased battery, was used to assess neurocognitive performance. Studies have produced
support for strong reliability with test-retest coefficients ranging from 0.65 to 0.88.
Concurrent validity comparing CNS Vital Signs battery to conventional tests has been
determined (Gualtieri, Johnson & Benedict, 2006). In a 2013 study by Bayan, practice
effects for this battery were explored using non-clinical and clinical samples. Significant
improvements in executive function, complex attention, and cognitive flexibility were
observed in the clinical sample only, suggesting that changes can be attributed to
treatment factors and not practice effects.
Seven conventional neuropsychological tests that span across cognitive domains
that are sensitive to most causes of cognitive dysfunction and which are known to be
reliable and valid comprise the CNS Vital Signs battery (Gualtieri & Johnson, 2006).
These include: Visual Memory (visual learning and memory), Verbal Memory (verbal
learning and memory), Finger Tapping (motor speed), Symbol Digit Coding (information
processing and visual-perceptual speed), Stroop Test (executive function), Shifting
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Attention Test (executive function), Continuous Performance Test (sustained attention).
From these 7 tests, domain scores in the following 10 categories are produced:
Neurocognition Index (NCI), Composite Memory, Verbal Memory, Visual Memory,
Processing Speed, Executive Function, Psychomotor Speed, Reaction Time, Complex
Attention, and Cognitive Flexibility.
Because this study aimed to evaluate domain scores for functions associated with
the prefrontal cortex, only the following were inspected: Executive Function, Cognitive
Flexibility, and Complex Attention. With the targeted sites of magnetic stimulation in
mind, prefrontal cortex functions were hypothesized to be the most robustly affected by
TMS treatment for depressed patients.
Executive Function tests measure one’s ability to recognize rules, categories, and
manage rapid decision-making. This predicts how well an individual can sequence tasks,
multi-task, and track and respond to a set of instructions. Cognitive Flexibility tests
capture the ability to adapt to a rapidly changing set of directions that progressively
increases in complexity. This ability is relevant to decision-making, reasoning, planning,
behavioral inhibition, and attentional abilities. Complex Attention tests measure accurate
and rapid vigilance as well as the ability to attend and respond to information for an
extended amount of time. This ability is relevant to exercising behavioral control. All
domain scores are reflected as raw scores, which are then converted to a standard score
for age (mean score is 100; standard deviation is 15).
As already discussed, the tests and test descriptions that form the above aggregate
domain scores are as follows: 1.) Symbol Digit Coding: serial presentations of screens,
each containing a row of 8 symbols with corresponding numbers, and a second row of 8
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symbols with empty boxes below.

The test taker is to type in the number that

corresponds with the symbol that is highlighted, 2.) Stroop Test: comprising of three
parts: first, pressing the space bar when the word appears on the screen; second, pressing
the space bar when the color of the word matches the word; third, pressing the space bar
when the color of the word does not match the word, 3.) Shifting Attention Test: shifting
from one instruction set to the next quickly and accurately by matching geometric objects
by color or shape, and 4.) Continuous Performance Test: responding to a target stimulus
presented on the screen, but not to any other stimulus presented.
Design and Statistical Analysis
For this study, using a Repeated Measures design, the neurocognitive effects of
TMS in the treatment of depression were evaluated over time. The repeated measures
factor was the neurocognitive assessments scores over three different time points (pretreatment, 2 weeks, post-treatment) for patients receiving TMS treatment on the RDLPFC
and SMA for MDD. An a priori power analysis was conducted to calculate the necessary
sample size. For this investigation, the alpha level, or Type 1 error rate, was set to a
standard .05. Statistical power was set to .8. At these specifications, it was determined
that a sample size of seven would be necessary to detect a Cohen’s d of .25 (partial η2 =
.577). Outlined below are the statistical analyses associated with each research question
listed above:
1.

A. Are there statistically significant differences in neurocognitive scores
following 2 and/or 6 weeks of rTMS treatment as compared to pre-treatment?
Three separate analyses were conducted, one for each cognitive domain (i.e.,
Executive Functioning, Complex Attention, Cognitive Flexibility) with
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repeated measures analysis of variance (ANOVA) comparing pre-treatment, 2
weeks of treatment, and post-treatment scores. Pearson correlations were
conducted to identify statistically significant potential covariates (e.g. BDI-II
and BAI baseline scores and score change, number of sessions, age, sex,
education level, and marital status) to be added to each analysis. Post-hoc
Tukey’s HSD analyses were used to elucidate any significant differences
observed.

B. If significant improvements in neurocognitive scores are found, do these
improvements occur independent of a reduction in depression and anxiety
scores? In order to distinguish between neurocognitive changes attributed to
TMS alone versus changes attributed to clinical improvement, six independent
correlational analyses were conducted assessing the relationship between
neurocognitive score change and both depression and anxiety score change.
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CHAPTER III
RESULTS
Sample Demographics
In order to characterize the sample, descriptive statistics were conducted for the
rTMS treatment group. Twenty total patients completed a course of rTMS for the
treatment of treatment-resistant depression. As seen on Table 1, the total mean age of the
20 patients was 42.35 with a standard deviation of 12.50 and comprised of primarily
females (25% males, 75% female) and those of Caucasian background (5% Asian, 5%
African American, 90% Caucasian). Patient education level fell between completion of
general education development (GED) and a master’s degree with the 50% of the sample
(N=10) achieving a bachelor’s or master’s degree. All patients met DSM-IV criteria for
Major Depressive Disorder, with minimum number of years suffering from
depressive/anxious symptoms being 2 years, maximum number of years being 30 years,
and a standard deviation of 8.46 years. Number of rTMS treatment sessions varied
according to multiple factors including treatment response and insurance allotment.
Treatment continuation was based on factors assessing clinical response, such as BDI-II
score decrease, subjective report by the patient, and clinical judgment by the study
psychiatrist and psychologist.
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Table 1
rTMS Group Demographic Data
Min
19

Max
59

M
42.35

SD
12.50

Number of years suffering from
Symptoms

2

30

17.15

8.46

Baseline BAI Score

10

42

26.55

9.34

Baseline BDI-II Score

18

56

40.75

9.37

Total Number of Sessions

16
N

38
%

34.95

4.61

Gender
Male
Female

5
15

25
75

Ethnicity
Caucasian
Asian
African American

18
1
1

90
5
5

Marital Status
Married
Divorced
Separated
Single

11
1
0
8

55
5
0
40

Highest Education
GED
HS Diploma
Some College
Associate’s Degree
Bachelor’s Degree
Master’s Degree
Doctorate Degree
Professional Degree (MD, JD)
Total

1
3
3
3
9
1
0
0
20

5
15
15
15
45
5
0
0

Age
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Research Question 1

Are there statistically significant differences in neurocognitive scores
following 2 and/or 6 weeks of rTMS treatment as compared to pre-treatment? Prior
to carrying out the research question 1 analyses, Pearson correlations were conducted to
assess for appropriate covariates to be included in the repeated measures ANOVA
(baseline, 2 weeks, post treatment). More specifically, correlations were conducted
between all potential covariates and each cognitive domain (Executive Functioning,
Complex Attention, Cognitive Flexibility) at each time point (pre-treatment, 2 weeks,
post-treatment). Bi-serial correlations were conducted for all continuous variables (e.g.,
BDI-II and BAI score pre- to post-treatment change, number of sessions, age, baseline
BDI-II and BAI scores), while categorical and ordinal variables (e.g., sex, education
level, and marital status) were tested using Spearman’s Rho analyses. Results, as seen on
Table 2, did not identify any significant covariates for all three baseline neurocognitive
domains (i.e., Executive Functioning, Complex Attention, Cognitive Flexibility).
This research question was examining whether a course of low-frequency, rightsided rTMS for the treatment of depression leads to changes in neurocognitive scores
throughout treatment. CNS Vital Signs was used to assess cognition at pre-treatment, 2
weeks, and end of treatment. However, only data for the cognitive domains associated
with functions implicated by the stimulation site (i.e., DLPFC): Executive Functioning,
Complex Attention, and Cognitive Flexibility were used to address this research question.
Three independent, repeated measures ANOVAs (baseline, 2 weeks, post treatment) were
conducted to compare standard mean score differences for each cognitive domain
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(Executive Functioning, Complex Attention, Cognitive Flexibility). All mean scores and
standard deviations are reported in Table 3.
The one-way repeated measure ANOVA demonstrated significant improvements
in executive function, F(1,19) = 9.76, p = .000, η2p = 0.339. Post-hoc Tukey’s LSD
analyses revealed that Executive Functioning mean scores at 2 weeks (102.95 ± 19.63)
and post-treatment (108.75 ± 12.94) were both significantly greater than pre-treatment
(88.25 ± 24.71) mean scores (p < .05). While there was a slight increase in mean score
from 2 week to post-treatment, this increase however was not statistically significantly
higher. Thus, in terms of Executive Functioning performance, significant improvements
were found after 2 weeks, with those gains remaining stable at post-treatment (Figure 1).
Similarly, the second repeated measure ANOVA conducted comparing
neurocognitive mean scores for Complex Attention, again showed significant
improvements when all three time points were accounted for, F(1,19) = 4.798, p = .014,
η2p = 0.202. Complex Attention mean scores at 2 weeks (90.25 ± 37.92) and posttreatment (99.15 ± 10.80) were both significantly greater than pre-treatment (76.55 ±
40.47) mean scores (p < .05). Also like Executive Functioning, while there was a slight
increase in mean score from 2 week to post-treatment, this increase was not statistically
significant (Figure 2).
The final repeated measure ANOVA showed Cognitive Flexibility, F(1,19) =
10.18, p = .000, η2p = 0.361, also differed significantly across the three time points. For
Cognitive Flexibility, post-hoc Tukey’s LSD tests revealed findings mirroring those of
Executive Functioning and Complex attention with statistically significant increases from
pre-treatment (84.50 ± 27.39) to 2 weeks (98.60 ± 21.41) and pre-treatment to post
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treatment (106.50 ± 12.58), but no statistically significant increases between 2 week and
post-treatment (Figure 3).

Table 2
Pearson Correlations between Potential Covariates and Neurocognitive Domain Scores
(Executive Functioning, Complex Attention, Cognitive Flexibility) at 3 Time Points (PreTreatment, 2 Weeks, Post-Treatment)
Variables

Executive Functioning

Complex Attention

Cognitive Flexibility

Pre

2w

Post

Pre

2w

Post

Pre

2w

Post

BDI-II score
change

-.30

-.30

-.09

-.16

-.29

-.08

-.28

-.39

-.12

BAI score
change

.01

.20

.16

.18

.33

.17

.02

.18

.11

# of Sessions

-.17

-.12

-.31

-.20

-.08

-.25

-.19

-.14

-.30

Baseline BDI

-.41

-.23

-.44

-.50*

-.19

-.33

-.48*

-.31

-.47

Baseline BAI

-.20

-.06

-.30

-.28

.03

-.24

-.25

-.05

-.29

Age

-.11

-.01

-.37

-.24

-.20

.05

-.15

-.14

-.37

Sex

-.27

-.17

-.13

-.07

-.06

.15

-.25

-.09

-.16

Marital Status

.19

.16

-.01

.29

.34

.25

.23

.27

-.00

Education Level

.50*

-.01

.20

.42

-.03

.44

.51*

.08

.26

* = p < .05
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Table 3
Means and Standard Deviations at Pre-Treatment, 2 weeks of treatment, and PostTreatment for Executive Functioning, Complex Attention, and Cognitive Flexibility
Neurocognitive Domains

Pre-Treatment
Mean (SD)

2 week (SD)

Post-Treatment
Mean (SD)

Executive
Functioning

88.25 (24.71)

102.95 (19.63)

108.75 (12.95)

Complex Attention

76.55 (40.47)

90.25 (37.92)

99.15 (10.80)

Cognitive Flexibility

84.47 (28.14)

99.32 (21.75)

106.37 (12.91)

115

Standard Scores

110
105
100
95
90
85
80
Pre-Treatment

2 Weeks

Post-Treatment

Figure 1. Executive Functioning 3-Time Point Standard Score Means
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110
105
Standard Scores

100
95
90
85
80
75
70
Pre-Treatment

2 weeks

Post-Treatment

Figure 2. Complex Attention 3-Time Point Standard Score Means

115
110
Standard Scores

105
100
95
90
85
80
75
Pre-Treatment

2 weeks

Post-Treatment

Figure 3. Cognitive Flexibility 3-Time Point Standard Score Means

Research Question 2
If significant improvements in neurocognitive scores are found, do these
improvements occur independent of a reduction in depression and anxiety scores?
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This research question examined whether neurocognitive improvements were more
prominently associated with stimulation of neuronal activity to the DLPFC. Correlational
analyses were conducted to examine the relationship between neurocognitive score
change from pre-treatment to post-treatment and depression and anxiety score change
from pre-treatment to post-treatment. Score change was calculated and represented as a
percentage in which the difference between pre-treatment and post-treatment scores is
divided by the pre-treatment score. Six Spearman’s rho correlational analyses were
conducted assessing the association between each neurocognitive domain (i.e., Executive
Functioning, Complex Attention, and Cognitive Flexibility) and BDI-II percent change
score and BAI percent change score. Results revealed that neither BDI-II nor BAI
change scores were significantly correlated with Executive Functioning change scores,
Complex Attention, or Cognitive Flexibility. Correlations are reported on Table 4.

Table 4.
Correlations between each Neurocognitive Domain Change Score and BDI-II and BAI
Change Scores Pre- to Post-Treatment
BDI-II (% Change)

BAI (% Change)

Executive Functioning
(% Change)

.176

.055

Complex Attention
(% Change)

.145

-.320

Cognitive Flexibility
(% Change)

.152

.053

*p< .05
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CHAPTER IV
DISCUSSION
TMS is emerging as a new and effective treatment alternative for the medication
and psychotherapy resistant population, which continues to demand clarification
regarding aspects of the treatment that can positively or negatively impact patient
functioning. For that reason, exploring the issue of neurocognitive functioning in this
patient population represents a significant contribution to the TMS and depression
literature.
The aim of the present study was to examine whether an experimental, lowfrequency dose of rTMS, which has been shown to contribute to treatment gains for
treatment-resistant depression in previous research but is not yet FDA approved, leads to
improvements in neurocognitive test scores from pre-treatment to post-treatment. This is
an imperative question to address as current literature only provides evidence of
neurocognitive change associated with a shorter course of treatment than has been found
to be the most clinically efficacious for sustained mood improvement or with treatment
limited to left sided treatment applications (George et al, 2010, O’Reardon et al., 2007,
Wasserman, 1998, Little et al., 2000; Speer et al., 2001; Avery et al., 1999; Padberg et al.,
1999; Triggs et al., 1999; Loo et al., 2001; Bayan, 2013). The study further aimed to
characterize the trajectory of neurocognitive change that occurs throughout the course of
treatment by examining neurocognitive score differences from pre-treatment to 2 weeks
to post-treatment. Specifically, do improvements exist after 2 weeks of treatment, and, if
so, do these improvements stabilize or further increase? Lastly, given that prior studies
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have evidenced neurocognitive improvements independent of positive mood changes
(Vanderhasselt et al., 2009, Rossi et al., 2009), the present study also examined whether
the evidenced neurocognitive improvements were associated primarily with improvement
of mood or stimulation of neuronal activity at the targeted treatment site (i.e., DLPFC).
Prior studies investigating neurocognitive effects associated with rTMS, have
offered evidence that rTMS is not associated with adverse neurocognitive effects.
Rather, previous studies have found improvement, or trends toward improvement, in the
neurocognitive domains of memory, executive functioning, and motor speed (Little et al.,
2000; Speer et al., 2001; Avery et al., 1999; Padberg et al., 1999; Triggs et al., 1999; Loo
et al., 2001, Moser et al., 2002, Martis et al., 2003, Schulze-Rauschenbach et al., 2005).
As previously mentioned, these studies utilized relatively shorter treatment session
frequencies (e.g., 5 to 15 sessions) than were implemented in the current study (i.e., 35
sessions) or were limited to left-sided treatments. However, it is theorized that a longer
treatment course is more likely to lead to greater, more sustainable effects in
neurocognition as has been found for treatment of depression with TMS. Thus, the
expected outcome was that rTMS would show a significant improvement in
neurocognitive scores from pre-treatment to post-treatment.
As expected, results of rTMS neurocognitive score data revealed statistically
significant improvements for all three neurocognitive domains (i.e., Executive
Functioning, Complex Attention, and Cognitive Flexibility) across the three time points
(i.e., pre-treatment, 2 weeks, and post-treatment). Regarding the differences between the
three time points (i.e., pre-treatment, 2 weeks, and post-treatment) it was hypothesized
that improvements in neurocognitive scores would be observed after 2 weeks of treatment
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with continued improvements (or increases) in scores at post-treatment. However, results
revealed statistically significant differences across test administrations only when all
three test administrations were accounted for in the model. Post-hoc analyses
demonstrated a pattern of statistically significant improvements in scores from pretreatment to 2 weeks. No statistically or clinically significant improvement or increase
was found from 2 week to post-treatment for Executive Functioning, Complex Attention,
and Cognitive Flexibility although scores did increase from 2 weeks to 6 weeks.
Therefore, in terms of change trajectory overall, based on the present results, it appears
that the greatest neurocognitive improvement takes place during the first two weeks of
treatment with a stabilizing (not declining) effect thereafter. Although the hypothesis that
a longer treatment course of rTMS will lead to greater neurocognitive improvements was
not supported, significant improvements in neurocognition were found nonetheless and
were supported by medium effect sizes. The observation that cognitive enhancements
associated with rTMS are predominantly accounted for in the first 2 weeks of treatment is
consistent with previous findings. In their systematic review, Guse, Falkai, and Wobrock
(2009) found that in the majority of studies subjects had 10 stimulation sessions in 2
weeks. The frequencies ranged from 10 Hz and 20 Hz, the motor threshold between 80
and 100%. In consideration of all positive cognitive outcomes, those studies using
stimulation over a period of 2-4 weeks seem to be most effective. Two studies, which
attained significant improving effects with 10-20 Hz, assessed five rTMS sessions only
(Moser et al., 2002; Triggs et al., 1999). In two other studies, participants received one
sham and one real rTMS session (Rektorova et al, 2005; Vanderhasselt et al., 2006). Five
studies were lacking significant cognitive improvement, but indicated a trend of cognitive
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amelioration (Boggin et al., 2005; Jorge et al., 2004; Loo et al., 2003; Mosimann et al.,
2004; Rosa et al., 2006).
Given the evidence that neurocognitive changes appear to take place fairly
quickly, further implies that neurocognitive change likely takes place independent of
positive mood changes, or improvements in depression and anxiety scores, since
abatement of this symptomology requires longer, more consistent stimulation of the
DLPFC to maintain activity (in this sample 4-6 weeks). The finding that neurocognitive
changes take place independent of mood changes was corroborated by Vanderhasselt et
al. (2009), who in fact did find improved scores on a test of executive functioning after
only one session of TMS in a depressed sample and no associated clinical improvement.
The present study further validates this finding and supports the hypothesis that neuronal
stimulation yields positive effects on neurocognition regardless of improvement in mood.
Results of the current study revealed changes in depression and anxiety scores that were
not significantly correlated with Executive Functioning, Complex Attention, and
Cognitive Flexibility change scores. This finding demonstrates the functional impact of
TMS’ role in stimulating neuronal activity in focal regions of the brain implicated with
particular cognitive functions and may suggest significant implications on the treatment
of neurocognitive deficits as a result of other neuropsychiatric and neurological illness or
injuries. Studies examining changes in cerebral functions following rTMS for a variety
of diagnoses are available and though findings are inconsistent, many demonstrate
selective cognitive improvement. When studying patients with schizophrenia Huber,
Schneider, and Rollnik (2003) found improvements in psychomotor speed for women
only when using high-frequency stimulation to the left DLPFC. In another study
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involving patients with schizophrenia, however, Sachdev, Loo, Mitchell, and Malhi
(2005) found no significant improvements. Martis, Alam, Dowd, et al., (2003) found
improvements in working memory, executive function, objective memory, and fine motor
speed for patients with bipolar when using 10Hz to the left DLPFC. Jorge, Robinson,
Tateno, et al., (2004) observed a trend toward general cognitive improvement in patients
with post-stroke depression when using 10 Hz to the left DLPFC. Boggio (2005)
evidenced a trend toward improvement in executive function when using 15 Hz to the left
DLPFC in patients with combined Parkinson’s disease and depression. In patients with
subjective memory complaints, Sole-Padulles, Bartres-Faz, Clemente, Mollineubevo, et
al. (2006) demonstrated improvements in associative memory. Finally, in a study by
Castel-Lacanal, Tarri, Loubinous, et al. (2014), found that following brain injury, rTMS
restored the interhemispheric interactions following stroke. Additional results showed
improvement in motor recovery, aphasia, and visuospatial neglect. Taken together, these
studies are promising but again, because findings are inconsistent, and because the
pathophysiological and neurobiological basis on these improvements is unclear,
additional studies including genetics, experimental neurophysiology, and functional brain
imaging are necessary to explore stimulation-related functional changes in the brain.
Limitations and Design Considerations
One major consideration and limitation of the current study is the small sample
size. It was evident that this was a major factor in under-powering potentially significant
results, particularly for post-hoc analyses. Patient recruitment and participation is often
limited and difficult to ascertain due to the continued lack of awareness of this treatment
option in addition to the high cost of the treatment and tentative insurance coverage.
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Even so, obtaining a larger sample size would enable not only the potential for greater
power and larger effect sizes, but it would also allow for a more representative sample of
depressed patients particularly with regard to baseline cognitive functioning. Sample bias
is likely to be an issue when sample size is severely limited, in combination with having a
treatment that is not as accessible to the general public. Given the high cost of this
treatment, the sample is liable to consist of individuals of higher socioeconomic status
(SES). Thus, a larger and more representative sample would allow for greater statistical
power and greater generalizability.
Another significant limitation relates to the lack of a depressed control group,
receiving standard treatment and not rTMS treatment, and completing the neurocognitive
battery at two different time points. This would allow controlling for possible placebo
effects associated with receiving rTMS versus no treatment or standard treatment.
However, the most beneficial and efficacious design would be the randomized-controlled
trial in which depressed patients are randomized to either a rTMS treatment condition or
a rTMS sham control condition. rTMS sham is a control device specially constructed for
research purposes, more specifically randomized-controlled trials. It mimics the sound
and sensation associated with rTMS treatment, without the neuronal stimulation. Thus,
both groups go through an identical procedure, which allows for a more powerful method
of controlling for placebo effects.
Participant selection procedures are typically meant to identify a subset of
depressed patients (i.e., treatment-resistant subset) that allows for greater homogeneity in
the sample. However, achieving homogeneity will always pose a major challenge given
that heterogeneity is rather inherent in the symptom and disease phenotype of depression.
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In this particular study, the sample was primarily comprised of Caucasian women with at
least a high school education. This of course limits the generalizability of findings. ,
Heterogeneity, as it pertains to depression severity, symptom rate of recovery, treatment
adherence, and concomitant medication treatment and/or psychotherapy, also poses
potential confounds that could significantly impact response to rTMS from a
neurocognitive standpoint. This could also be greatly controlled for via a randomizedcontrol study design. In a randomized-controlled study, the act of randomly assigning
subjects to either the intervention (receiving TMS treatment) or control (receiving sham
TMS) group ensures that, on average, no systematic differences (i.e., factors listed above)
exists between groups and thus outcomes can be seen as attributable solely to the
intervention.
Another potential limitation is the battery utilized to assess the specific functions
implicated with the DLPFC. While CNS Vital Signs has shown promising reliability and
validity properties, particularly in its utility for research in a clinical setting (Gualtieri &
Johnson, 2006), it is possible that more extensive testing of the targeted domains (e.g.
attention and executive functioning) would provide a more accurate representation of
each group’s neurocognitive profile.
Similar to many other rTMS studies, this study was limited by the lack of followup measures. It is therefore unknown how long the observed effects of rTMS on
cognitive function will persist. However, while the duration of the induced cognitive
effects are lacking, one can assume, based on remaining effects of psychopathology from
other studies (e.g. improvement of mood), cognitive improvement will persist for a
period of time.
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A final limitation concerns the positioning of the coil. This study used the
Pascual-Leone method whereby the coil was placed 5 cm rostrally from the hot spot of
the primary motor cortex to identify the DLPFC and 2 cm rostrally to identify the SMA.
Neuronavigation studies have shown that individual fMRI-guided TMS neuronavigation
yielded the strongest behavioral effect size as compared to an EEG-system approach and
the Pascual-Leone method (Sack et al., 2009). It may therefore stand to reason that
cognitive changes may be impacted by correct coil positioning.
The aforementioned limitations demand a careful analysis of the findings and
interpretations. First, while no significant changes in cognitive functioning were
evidenced from 2 weeks to post-treatment, it may be possible that in fact, longer
treatment does result in greater change, but can only be evidenced by a larger sample size
or by more precise coil positioning. At the same time, it is also possible that cognitive
improvements may be more likely in certain treatment-resistant patient cohorts like those
represented in this sample and thus, generalizing these findings should be done
cautiously. The direct influence of rTMS on cognitive enhancement also should be
considered thoughtfully due to the number of potential confounds and the possibility of
placebo effects. It may also be that because of the close connection and intradependability of the cognitive abilities associated with the frontal cortex, along with the
psychometric limitations of the tests used to measure them, results only point to general
cognitive domain improvements and do not specifically delineate between them. Finally,
while the cognitive improvements shown in this study are exciting, their durability is not
known.
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Conclusions
The present study was able to contribute to the current empirical knowledge
maintaining rTMS’ safe and beneficial use for treatment-resistant depression (TRD).
More specifically, it substantiates the use of right-sided, low-frequency rTMS as a
treatment alternative to ECT as it preserves cognitive functions. It extends the existing
evidence for the ongoing case in making rTMS a first line of treatment for TRD with
further elucidation of additional rTMS treatment parameter options. This study also
provided support for improved functions associated with frontal-lobe functioning:
executive functioning, attention, and cognitive flexibility. This is of paramount
significance as these are functions necessary for optimal functioning and overall wellbeing.
The results of this study also helped to facilitate the understanding of how
functional processes are actuated by these neurophysiological and neuroplastic changes in
the brain. Previous brain imaging studies have demonstrated metabolic and cerebral
blood flow alterations in the DLPFC, as well as in other limbic, paralimbic, frontal and
prefrontal regions, after application of rTMS (Kito, Fujita & Koga, 2008, Spear et al.,
2000, Kito et al., 2009). Furthermore, there has been evidence of grey matter density
alterations in direct and remote areas of the site of rTMS stimulation after as little as five
days of treatment, as well as direct evidence of rTMS-induced long-term potentiation in
humans after a single train of repetitive stimulation (May et al, 2006; Esser et al, 2006).
This study adds to this by demonstrating a clear pattern of neurocognitive improvements
that tend to take place sometime during the initial 2 weeks of treatment. In addition to
elucidating this neurocognitive change pattern, the current study also corroborated the
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finding that improvements are associated with low frequency rTMS and that they occur
independent of mood changes, thus likely a direct effect of neuronal stimulation. This is
an important contribution to the rTMS literature as it allows for broader treatment
implications for neurocognitive impairment caused by other injuries or pathologies, such
as the effects of stroke, TBI, or Parkinson’s. This opens up the possibility for research to
investigate the utility of TMS in stimulating underactive or damaged regions of the brain
identified by MRI, for example, which is also having significant cognitive or functional
effects on the patient and warranting some form of intervention. Because the TMS
effects on cognition are also relatively quick (2 weeks), it also serves as a treatment
option that is not time consuming or as costly as current rTMS treatment courses for
neuropsychiatric disorders. However, with that said, further investigation into the
durability of cognitive effects, the influence of potential confounds and placebo effects,
and the generalizability of these findings is still necessary. This would be ideally
accomplished with a randomized clinical trail, which includes a sham condition.
Demonstrating TMS’ capacity for neurocognitive improvement is believed to be a
substantial finding that can greatly facilitate a much larger and broader role for TMS in
the field of neuropsychiatry. However, the provision of evidence of sustainable gains in
cognition will prove to be prolific beyond the field of neuropsychiatry.

64

REFERENCES

Arbisi, P.A. (1996). Review of the Beck Depression Inventory-II. Mental Measurements
yearbook. Retrieved from EBSCO Mental Measurements Yearbook database.
Avery, D. H., Claypoole, K., Robinson, L., Neumaier, J. F., Dunner, D. L., Scheele, L., &
Roy-Byrne, P. (1999). Repetitive transcranial magnetic stimulation in the
treatment of medication-resistant depression: preliminary data. The Journal of
Nervous and Mental Disease, 187, 114–117.
Banich, M. T. (2004). Cognitive neuroscience and neuropsychology. Boston: Houghton
Mifflin Corporation.
Bayan, S. M. (2013). Neurocongitive changes associated with 6 to 9 weeks of
transcranial magnetic stimulation in the treatment of major depressive disorder
(unpublished doctoral dissertation). Virginia Consortium Program in Clinical
Psychology, Norfolk, Virginia.
Barker, A. T. (1991). An introduction to the basic principles of magnetic nerve
stimulation. Journal of Clinical Neurophysiology, 8(1), 26-37.
Barker, A. T. & Freeston, I. (2007). Transcranial magnetic stimulation. Scholarpedia,
2(10):2936. Doi:10.4249/scholarpedia.2936
Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988). An inventory for measuring
clinical anxiety: Psychometric properties. Journal of Consulting and Clinical
Psychology, 56(6), 893-897.
Beck, A. T., Steer, R. A., & Brown, K. G. (1996). Beck Depression Inventory (2nd ed.).
San Antonio, A: Harcourt Brace & Company.

65

Beck, A. T., & Steer, R. A. (1987). Beck anxiety inventory manual. San Antonio:
Psychological Corporation.
Bell, I. R., Schwartz, G. E., Hardin, E. E., Baldwin, C. M., & Kline, J. P. (1998).
Differential resting quantitative electroencephalographic alpha patterns in women
with environmental chemical intolerance, depressives, and normal. Biological
Psychiatry, 43, 376-388.
Berry, S. M., Broglio, K., Bunker, M., Jayewardene, A., Olin, B., Rush, J. A. (2013). A
patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy
for treatment-resistant depression. Medical Devices: Evidence and Research, 6,
17-35.
Bohning, D. E., Shastri, A., McConnell, K. A., Nahas, Z, Lorberbaum, J. P., Roberts, D.
R., Teneback, C., Vincent, D. J., & George, M. S. (1999). A combined
TMS/fMRI study of intensity-dependent TMS over motor cortex. Biological
Psychiatry, 45(4), 385-394.
Boggio, P.S., Fregni, F., Bermpohl, F., Mansure, C. G., Rosa, M., Rumi, D. O., Barbosa,
E. R., Rosa, M. O., Pascual-Leone, A., Rigonatti, S. P., Marcolin, M. A., Silva,
M. T. A. (2005). Effect of repetitive TMS and fluoxetine on cognitive function in
patients with Parkinson’s disease and concurrent depression. Brief Reports, 20(9),
1178-1219.
Bremner, J. D., Innis, R. B., Salomon, R. M., Staib, L. H., Ng, C. K., Miller, H. L.,
Bronen, R. A., Krystal, J. H., Duncan, J., Rich, D., Price, L. H., Malison, R., Dey,
H., Soufer, R., Charney, D. S. (1997). Positron Emission tomography
measurement of cerebral metabolic correlates of tryptophan depletion-induced

66

depressive relapse. Archives of General Psychiatry, 54, 364-374.
Brody, A. L., Saxena, S., Manderlkern, M. A., Fairbanks, L. A., Ho, M. L., Baxter, L. R.
(2001). Brain metabolic changes associated with symptom factor improvement in
major depressive disorder. Biological Psychiatry, 50(3), 171-178.
Burt, D. B., Zembar, M. J., & Niederehe, G. (1995). Depression and memory
impairments: A metaanalysis of the association, its pattern, and specificity.
Psychological Bulletin, 117, 285-305.
Caspi, A. Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., McClay, J.,
Mill, J., Martin, J., Braithwaite, A., & Poulton, R. (2003). Influence of life stress
on depression: moderation by a polymorphism in the 5-HTT gene. Science, 301,
386-390.
Castel-Lacanal, E., Tarri, M., Loubinoux, I., Gasq, D., Boissexon, X., Marque, P.,
Simonetta-Moreau, M. (2014). Transcranial magnetic stimulation in brain injury.
French Annuals of Anesthesia, 33, 83-87.
Cicchetti, D., Rogosch, F. A., & Sturge-Apple, M. I. (2007). Interactions of child
maltreatment and serotonin transporter and monamine oxidase A polymorphism:
depressive symptomatology among adolescents from low socioeconomic status
backgrounds. Developmental Psychology, 19, 1161-1180.
Ciprani, A., Girlanda, F., Agrimi, E., Barichello, A., Beneduce, R. Bighelli, I., Bisogno,
A., Bortolaso, P., Boso, M., Calandra, C., Cascone, L., Corbascio, C., Parise, V.
F., Gardellin, F., Gennara, D., Hanife, B., Lintas, C., Lorusso, M., Luchetta, C.,
Lucii, C., Cernuto, F., Tozzi, F., Marsilio, A., Maio, F., Mattei, C., Moretti, D.,
Appino, M. G., Nose, M., Occhionero, G., Papanti, D. Pecile, D., Purgato, M.,

67

Prestia, D., Restaino, F., Sciarma, T., Ruberto, A., Strizzolo, S., Tamborini, S.,
Todarello, O., Ziero, S., Zotos, S., & Barbui, C. (2013). Effectivness of lithium in
subjects with treatment-resistant depression and suicide risk: a protocol for
randomised, independent, pragmatic, multicenter, parallel-group, superiority
clinical trail. BMC Psychiatry 13, 212-219.
Cools, R. Calder, A. J., Lawrence, A. D., Clark, L., Bullmore, E., & Robbins, T. W.
(2005). Individual differences in threat sensitivity predict serotonergic modulation
of amygdala response to fearful faces. Psychopharmacology, 180, 670-679.
Davidson, R. J., Lewis, D. A., Alloy, L. B., Amaral, D. G., Bush, G., Cohen, J. D.
Drevets, W. C., Farah, M. J., Kagan, J., McClelland, J. L., Nolen-Hoeksema, S.,
& Peterson, B. S., (2002). Neural and behavioral substrates of mood and mood
regulation. Biological Psychiatry, 52, 478-502.
Davidson, R. J., Pizzagalli, D., Nitschke, J. B., Putnam, K. (2002). Depression:
Perspectives from Affective Neuroscience. Annual Review of Psychology, 53,
545-574.
Debener, S., Beauducel, A., Nessler, D., Brocke, B., Heilemann, H., Kayser, J. (2000). Is
resting anterior EEG alpha asymmetry a trait marker for depression? Findings for
healthy adults and clinically depressed patients. Neuropsychobiology, 41, 31-37.
Dowd, E. T. (2010). Review of the beck anxiety inventory. Mental Measurements
Yearbook. Retrieved from EBSCO Mental Measurements Yearbook database.
Drevets, W. C., Bogers, W., & Raichle, M. E. (2002). Functional anatomical correlates of
antidepressant drug treatment assessed using PET measures of regional glucose
metabolism. European Neuropsychopharmacology, 12, 527-544.

68

Drevets, W. C., Price, J. L., Simpson, J. R., Todd, R. D., Reich, T., Vannier, M., &
Raichle, M. E. (1997). Subgenual prefrontal cortex abnormalities in mood
disorders. Nature, 386, 824-827.
Dunlop, B. W. and Nemeroff, C. B. (2007). The role of dopamine in the pathophysiology
of depression. Archives of General Psychiatry, 4, 327-337.
Esser, S. K., Huber, R., Massimini, M., Peterson, M. J., Ferrarelli, F., & Tononi, G.
(2006). A direct demonstration of cortical LTP in humans: A combined
TMS/EEG study. Journal of Brain Research, 69(1), 86–94.
Fava, M. & Davidson, K. G. (1996). Definition and epidemiology of treatment-resistent
depression. Psychiatric Clinics of North America, 19(2), 179-200.
Fava, M., Graves, L. M., Benazzi, F., Scalia, M. J., Iosifescu, D. V., Alpert, J. E., &
Papakostas, G. I. (2006). A cross-sectional study of the prevalence of cognitive
and physical symptoms during long-term antidepressant treatment. The Journal of
Clinical Psychiatry, 67, 1754-1759.
Fava, G. A., Savron, G., Grandi, S., Rafanelli, C. (1997). Cognitive-behavioral
management of drug-resistant major depressive disorder. Journal of Clinical
Psychiatry, 58(6), 278-282.
Fernandes, L. O. L., Keller, J., Giese-Davis, J. E., Hicks, B. D., Klein, D. N., & Miller,
G. A. (1999). Converging evidence for a cognitive anolmaly in early
psychopathology. Psychophysiology, 36, 511-521.
Fitzgerald, P. B., Benitez, J., deCastella, A., Brown, T. L., Daskalakis, Z. J., Kulkarni, J.
(2006). Naturalistic study of the use of transcranial magnetic stimulation in the
treatment of depressive relapse. Australian and New Zealand Journal of

69

Psychiatry, 40(9), 764-768.
Fitzgerald, P. B., Benitez, J., de Castella, A., Daskalakis, Z. J., Borwn, T. L., Kulkarni, J.
(2006). A randomized, controlled trial of sequential bilateral repetitive
transcranial magnetic stimulation for treatment-resistant depression, American
Journal of Psychiatry, 163(1), 88-94.
Fitzgerald, P. B. & Daskalakis, Z. J. (2012). A practical guide to the use of repetitive
transcranial magnetic stimulation in the treatment of depression. Brain
Stimulation, 5, 287-296.
Fitzgerald, P. B., Fountain, S., & Daskalakis, Z. J. (2006). A comprehensive review of
the effects of rTMS on motor excitability and inhibition, Clinical
Neurophysiology, 117(12), 2584-2596.
Fresco, D. M., Heimberg, R. G., Abramowitz, A., & Bertram, T. L. (2006). The effect of
a negative mood priming challenge on dysfunctional attitudes, explanatory styple,
and explanatory flexibility. The British Journal of Clinical Psychology/The
British Psychological Society, 45, 167-183.
George, M. S., Lisanby, S. H., Avery, D., et al. (2010). Daily left prefrontal transcranial
magnetic stimulation therapy for major depressive disorder: a sham-controlled
randomized trail. Archives of General Psychiatry, 67(5), 507-516.
George, M. S., Wasserman, E. M., Williams, W. A., Steppel, J., Pascual-Leone, A.,
Basser, P., Hallett, M., & Post, R. M. (1996). Changes in mood and hormone
levels after rapid-rate transcranial magnetic stimulation (rTMS) of the prefrontal
cortex. Journal of Neuropsychiatry Clinical Neuroscience, 172-180.
Gotlib, I. H. & Hamilton, J. P. (2008). Neuroimaging and depression: Current status and

70

unresolved issues. Association of Psychological Services, 17(2), 159-163.
Gotlib, I. H., Joorman, J. (2010). Cognition and depression: Current status and future
directions. Annual review of Clinical Psychology, 6, 285-312.
Gualtieri, C. T. & Johnson, L. G. (2006). Reliability and Validity of a Computerized
Neurocognitive Test Battery, CNS Vital Signs. Archives of Clinical
Neuropsychology, 21, 623-643.
Gualtier, C. T., Johnson, L. G., & Benedict, K. B. (2006). Neurocognition in depression:
Patients on and off medication versus healthy comparison subject. Journal of
Neuropsychiatry and Clinical Neuroscience, 18(2), 217-225.
Guse, B., Falkai, P., Wobrock, T. (2010). Cognitive effects of high-frequency repetitive
transcranial magnetic stimulation: a systematic review. Journal of Neural
Transmission, 117, 105–122.
Hanajima, R., Wang, R., Naktatani-Enomoto, S., Hamanda, M., Terao, Y., Furubayashi,
T., Okabe, S., Inomata-Terada, S., Yugeta, A., Rothwell, J. C., & Ugawa, Y.
(2007). Comparison of different methods for estimating motor threshold with
transcranial magnetic stimulation. Clinical Neurophysiology, 118(9), 2120-2122.
Hankin, B. L. & Abramson, L. Y. (2001). Development of gender differences in
depression: an elaborated cognitive vulnerability-transactional stress theory.
Psychological Bulletin, 127(6), 773-796.
Heller, W., Nitschke, J. B., Etienne, M. A., & Miller, G. A. (1997). Patterns of regional
brain activity differentiate types of anxiety. Journal of Abnormal Psychology,
106, 376-385.
Heller, W., & Nitschke, J. B. (1997). Regional brain activity in emotion: A framework

71

for understanding cognition in depression. Cognition and Emotion, 11, 638-661.
Herrera-Guzman, I., Gudayol-Ferre, E., Jarne-Esparcia, A., Herrera-Abarca, J. E.,
Herrera-Guzman, D., Pero-Cebollero, M., Guardia-Olmos, J. (2009).
Comordibidy of anxiety disorders in major depressive disorder. A clinical trail to
evaluation neuropsychological deficit. The European Journal of Psychiatry, 23(1),
5-18.
Hertel, P. T. (1994). Depression and memory: are impairments remediable through
attentional control? Current Direction in Psychological Science, 3, 190-194.
Herwig, U., Fallgatter, A. J., Hoppner, J., Eschweiler, G. W., Kron, M., Hajak, G.,
Padberg, F., Naderi-Heiden, A., Abler, B., Eichhammer, P., Grossheinrich, N.,
Hay, B., Kammer, T., Languth, B., Laske, C., Plewnia, C., Richter, M. M.,
Schulz, M., Unterecker, S., Zinke, A., Spitzer, M., & Schonfeldt-Lecuona, C.
(2007). Antidepressant effects of augmentative transcranial magnetic stimulation:
randomized multicenter trial. British Journal of Psychiatry, 191, 441-448.
Hindmarch, I. (2001). Expanding the horizons of depression: beyond the monoamine
hypothesis. Human Psychopharmacology, 16, 203-218.
Hooley, J. M., Gruber, S. A., Scott, L. A., Hiller, J. B., & Yurfelun-Todd, D. A. (2005).
Activation in dorsolateral prefrontal cortex in response to maternal criticism and
praise in recovered depressed and health control participants, Biological
Psychiatry, 57, 809-812.
Huber, T. J., Schneider, U., Rollnik, J. (2003). Gender differences in the effect of
repetitive transcranial magnetic stimulation in schizophrenia. Psychiatry
Research, 120(1), 103-105.

72

Hufnagel, A., Claus, D., Brunhoelzl, C., & Sudhop, T. (1993). Short-term memory: no
evidence of effect of rapid-repetitive transcranial magnetic stimulation in healthy
individuals. Journal of Neurology, 240(6), 373–376.
Jahanshahi, M., Ridding, M. C., Limousin, P., Profice, P., Fogel, W., Dressler, D., Fuller,
R., Brown, R. G., Brown, P., & Rothwell, J. C. (1997). Rapid rate transcranial
magnetic stimulation-a safety study. Electroencephalography and Clinical
Neurophysiology, 105(6), 422-490.
Janicak, P. G., Nahas, Z., Lisanby, S. H., Solvason, H. B., Sampson, S. M., McDonald,
W. M., Marangell, L. B., Rosenquist, P., McCall, W. V., Kimball, J., O’Reardon,
J. P., Loo, C., Husain, M. H., Krystal, A., Gilmer, W., Dowd, S. M., Demitrack,
M. A., & Schatzberg, A. F. (2010). Durability of clinical benefit with transcranial
magnetic stimulation (TMS) in the treatment of pharmacoresistant major
depression: assessment of relapse during a 6-month multisite, open-label study.
Brain Stimulation, 3(4), 187-199.
Jelovac, A., Kolshus, E., & McLoughlin, D. M. (2013). Relapse following successful
treatment electroconvulsive therapy for major depression: a meta-analysis.
Neuropsychopharmacology, 38(12), 2467-2474.
Jorge, R. E., Robinson, R. G., Tateno, A., Narushima, K., Acion, L., Moser, L., Arndt, S.,
Chemerinski, E. (2004). Repetitive transcranial magnetic stimulation as treatment
of poststroke depression: a preliminary study. Biological Psychiatry, 55, 398-405.
Juckel, G., Mendlin, A., & Jacobs, B. L. (1999). Electrical stimulation of rat medial
prefrontal cortex enhances forebrain serotonin output: implications for
electroconvulsive therapy and transcranial magnetic stimulation in depression.

73

Neuropsychopharmacology, 21(3), 391-398.
Keller, J., Isaacks, B. G., Wesemann, D., Gergan, J. A., & Miller, G. A. (1999).
Diagnostic and cognitive specificity of memory deficits in psychopathology. Paper
presented at the annual meeting of the Cognitive Neuroscience Society,
Washington, D. C.
Kito, S., Hasegawa, T., & Koga, Y. (2011). Neuroanatomical correlates of therapeutic
efficacy of low-frequency right prefrontal transcranial magnetic stimulation in
treatment resistant depression. Psychiatry and Clinical Neurosciences, 65, 175182.
Levens, S. M. & Gotlib, I. H. (2009). Impaired selection of relevant positive information
in depression. Depression and Anxiety, 26, 403-410.
Levin, R. L., Heller, W., Mohanty, A., Herrington, J. D., Miller, G. A. (2007). Cognitive
deficits in depression and functional specificity of regional brain activity.
Cognitive Therapy and Research, 31, 211-233.
Lisanby, S. H., Kinnunen, L. H., & Crupian, M. J. (2002) Applications of TMS to therapy
in psychiatry. Journal of Neurophysiology, 18, 211-233.
Little, J. T., Kimbrell, T. A., Wassermann, E. M., Grafman, J., Figueras, S., Dunn, R. T.,
Post, R. M. (2000). Cognitive effects of 1- and 20-Hz repetitive transcranial
magnetic stimulation in depression: Preliminary report. Neuropsychiatry,
Neuropsychology, and Behavioral Neurology, 13, 119–24.
Loo, C. K., McFarquhar, T. F., Mitchell, P. B. (2008). A review of the safety of repetitive
transcranial magnetic stimulation as a clinical treatment for depression,
International Journal of Neuropsychopharmacology, 11(1), 131-147.

74

Loo, C., Sachdev, P., Elsayed, H., McDarmont, B., Mitchell, P., Wilkinson,
M.,…Gandevia, S. (2001) Effects of a 2-–4-week course of repetitive transcranial
magnetic stimulation (rTMS) on neuropsychologic functioning,
electroencephalogram, and auditory threshold in depressed patients. Biological
Psychiatry, 49, 615–623.
Luber, B., & Lisanby, S. H. (2013). Enhancement of human cognition performance using
transcranial magnetic stimulation (TMS). Neuroimage, 85, 961-970.
Machado, M., Iskedjian, M., Ruiz, I., Einasrson, T. M. (2006). Remission, dropouts, and
adverse drug reaction rates in major depressive disorder a meta-analysis of headto-head trials. Current Medical Research and Opinion, 22(9), 1825-1837.
Martis, B., Alam, D., Dowd, S. M., Hill, S. K., Sharma, R. P., Rosen, C.,…Janicak, P. G.
(2003). Neurocognitive effects of repetitive transcranial magnetic stimulation in
severe major depression. Clinical Neurophysiology, 114, 1125–1132.
May, A., Hajak, G., Gansbauer, S., Steffens, T., Langguth, B., Kleinjung, T., &
Eichhammer, P. (2007). Structural brain alterations following 5 days of
intervention: dynamic aspects of neuroplasticity. Cerebral Cortex, 17, 205–210.
Mayberg, H. S., Liotti, M., Brannan, S. K., McGinnis, S., Mahurin, R. K., Jerabek, P. A.,
Silva, J. A., Tekell, J. L., Martin, C. C., Lancaster, J. L., & Fox, P. T. (1999).
Reciprocal limbic-cortical function and negative mood: Converging PET findings
in depression and normal sadness. American Journal of Psychiatry, 156, 675-682.
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C.,
Schwalb, J. M., Kennedy, S. H. (2005). Deep brain stimulation for treatment
resistant depression, Neuron, 45, 651-660.

75

Miret, M., Ayuso-Mateos, J. L., Sanchez-Moreno, J., &Vieta, E. (2013). Depressive
disorders and suicide: Epidemiology, risk factors, and burden, Neuroscience and
Biobehavioral Reviews, 37, 2372-2374.
Moser, D. J., Jorge, R. E., Manes, F., Paradiso, S., Benjamin, M. L., & Robinson, R. G.
(2002). Improved executive functioning following repetitive transcranial magnetic
stimulation. Neurology, 58(8), 1288–1290.
Murrough, J. W., Iacoviell, B., Neumeister, A., Charney, D. S., Iosifescu, D. V. (2011).
Cognitive dysfunction in depression: neurocircuitry and new therapeutic
strategies. Neurobiology of Learning and Memory, 96, 553-563.
Nemeroff, C. B. (1996). The corticotropin-releasing factor (CRF) hypothesis of
depression: new findings and new directions. Molecular Psychiatry, 1, 336-342.
Nemeroff, C. B., Estsuah, R., Benattia, I., Demitrack, M. Sloan, D. M., & Thase, M. E.
(2008). Comprehensive Analysis of Remission (COMPARE) with Venlafaxine
versus SSRIs. Biology of Psychiatry, 63, 424-434.
Nitschke, J. B., Heller, W., & Miller, G. A. (2000). Anxiety, stress, and cortical brain
function. The neuropsychology of emotion, 298-319.
Nobler, M. S., Sackeim, H. A., Prohovnik, I., Moeller, J. R., Mukherjee, S., Schnur, D.
B., Prudic, J., Devanand, D. P. (1994). Regional cerebral blood flow in mood
disorders, III. Treatment and clinical response. Archives of General Psychiatry,
51(11), 884-897.
O’Reardon, J. P., Peshek, A. D., Romero, R., & Cristancho, P. (2006). Neuromodulation
and Transcranial Magnetic Stimulation, Psychiatry, 3(1), 30-40.
O’Reardon, J. P., Solvason, H. B., Janicak, P.G. (2007). Efficacy and safety of

76

transcranial magnetic stimulation in the acute treatment of major depression: a
multisite randomized controlled trail. Biological Psychiatry, 62(11), 1208-1216.
Padberg, F., George, M. S. (2009). Repetitive transcranial magnetic stimulation of the
prefrontal cortex in depression. Experimental Neurology, 219, 2-13.
Padberg, F., Zwanzger, P., Thoma, H., Kathmann, N., Haag, C., Greenberg, B. D.,
Moller, H. J. (1999). Repetitive transcranial magnetic stimulation (rTMS) in
pharmacotherapy-refractory major depression: Comparative study of fast, slow
and sham rTMS. Psychiatry Research, 88, 163–171.
Pascual-Leone, A., Houser, C. M., Reese, K., Shotland, L. I., Grafman, J., Sato, S….&
Cohen, L. G. (1993). Safety of rapid-rate transcranial magnetic stimulation in
normal volunteers. Electroencepholopathy and Clinical Neurophysiology, 89,
120–130.
Rektorova, I., Megova, S., Bares, M., Rektor, I. (2005). Cognitive functioning after
repetitive transcranial magnetic stimulation in patients with cerebrovascular
disease without dementia: a pilot study of seven patients. Journal of Neurological
Science, 229-230, 157-161.
Rogers, M. A., Kasai, K., Koji, M. Fukuda, R., Iwanami, A., Nakagome, K., Fukuda, M.,
& Kato, N. (2004). Executive and prefrontal dysfunction in unipolar depression: a
review of neuropsychological and imaging evidence. Neuroscience Research, 50,
1-11.
Rossi, S., Hallett, M., Rossini, P., & Pascual-Leone, A. (2009). Safety, ethical
considerations, and application guidelines for the use of transcranial magnetic

77

stimulation in clinical practice and research. Clinical Neurophysiology, 120,
2008–2039.
Rot, Marije, Mathew, S. J., Charney, D. S. (2009). Neurobiological mechanisms in major
depressive disorder. Canadian Medical Association Journal, 180(3), 305-313.
Sachdev. P., Loo, C., Mitchell, P., Malhi, G. (2005). Transcranial magnetic stimulation
for the deficit syndrome of schizophrenia: A pilot investigation. Psychiatry and
Clinical Neuroscience, 59(3), 354-357.
Santiago-Rodriguez, E., Cardenas-Morales, L, Harmony, T., Fernandez-Bouzas, A.,
Porras, Kattz, E., Hernandez, A. (2008). Repetitive transcranial magnetic
stimulation decreases the number of seizures in patients with focal neurocortical
epilepsy. Seizure, 17(8), 677-683.
Schulze-Rauschenbach, S. C., Harms, U., Schlaepfer, T. E., Maier, W., Falkai, P., &
Wagner, M. (2005). Distinctive neurocognitive effects of repetitive transcranial
magnetic stimulation and electroconvulsive therapy in major depression, Bristish
Journal of Psychiatry, 186, 410-416.
Schutter, D. J. (2009). Antidepressant efficacy of high-frequency transcranial magnetic
stimulation over the left dorsolateral prefrontal cortex in double-blind shamcontrolled designs: a meta-analysis. Psychological Medicine, 39(1), 65-75.
Schutter, D. J. (2010). Quantitative review of the efficacy of slow-frequency magnetic
brain stimulation in major depressive disorder, Psychological Medicine, 27, 1-7.
Sheline, Y. I., Barch, D. M., Donnelly, J. M., Ollinger, J. M., Snyder, A. Z., & Mintun,
M. A. (2001). Increased amygdala response to masked emotional faces in
depressed subjects resolves with antidepressant treatment: an fMRI study.

78

Biological Psychiatry, 50(9), 651-658.
Siegle, G. J., Carter, C. S., & Thase, M. E. (2006). Use of fMRI to predict recovery from
unipolar depression with cognitive behavior therapy. American Journal of
Psychiatry, 163, 735-738.
Slotema, C. W., Blom, J.D., Hoek, H. W., Sommer, I. E. (2010). Should we expand the
toolbox of psychiatric treatment methods to include Repetitive Transcranial
Magnetic Stimulation (rTMS)? A metaanalysis of the efficacy of rTMS in
psychiatric disorders. Journal of Clinical Psychiatry, 71(7), 873-884.
Sole-Padulles, C., Bartres-Faz, D. Junque, C., Clemente, I. C., Molinuevo, J. L., Bargallo,
N., Sanchez-Aldeguer, J., Bosch, B., Falcon, C., Valls-Sole, J. (2006). Repetitive
transcranial magnetic stimulation effects on brain function and cognition among
elders with memory dysfunction. A randomized sham-controlled study. Cerebral
Cortex, 16, 1487-1493.
Speer, A. M., Repella, J. D>, Figueras, B. A., Demian, N. K., Kimbrell, T. A.,
Wasserman, E. M., Post, R. M. (2001). Lack of adverse cognitive effects of 1 Hz
and 20 Hz repetitive transcranial magnetic stimulation at 100% of motor threshold
over left prefrontal cortex in depression. The Journal of ECT, 17(4), 259-263.
Strafella, A. P., Paus, T., Barrett, J., Dagher, A. (2001). Repetitive transcranial magnetic
stimulation of the human prefrontal cortex induces dopamine release in the
caudate nucleus. The Journal of Neuroscience, 21, 1-4.
Takahashi, M., Shirayama, Y., Muneoka, K., Suzuki, M., Sato, K., & Hashimoto, K.
(2013) Low Openness on the NEO Personality Inventory as a Risk Factor for
Treatment-Resistant Depression, PLoS ONE 8(9): e7 1964. doi:

79

10.1371/journal.pone.0071964
Thase, M. E., Friedman, E. S., Howland, R. H. (2001). Management of treatmentresistant depression: psychotherapeutic perspectives. Journal of Clinical
Psychiatry, 62, 18-24.
Thase, M. E., Greenhouse, J. B., Frank, E., Reynolds, C. F., Pilkonis, P. A., Hurley, K.,
Grochocinski, V., Kupfer, D. J. (1997). Treatment of major depression with
psychotherapy or psychotherapy-pharmacotherapy combinations. Archives of
General Psychiatry, 54(11), 1009-1015.
Triggs, W. J., McCoy, K. J., Greer, R., Rossi, F., Bowers, D., Kortenkamp, S., Goodman,
W. K.(1999). Effects of left frontal transcranial magnetic stimulation on
depressed mood, cognition, and corticomotor threshold. Biological Psychiatry,
45, 1440–1446.
Turnier-Shea, Y., Bruno, R., Pridmore, S. (2006). Daily and spaced treatment with
transcranial magnetic stimulation in major depression: a pilot study. Australian
and New Zealand Journal of Psychiatry, 40(9), 759-763.
Vanderhasselt, M., Raedt, R. D., Baeken, C., Leyman, L., & D'Haenen, H. (2009). A
single session of rTMS over the left dorsolateral prefrontal cortex influences
attentional control in depressed patients. The World Journal of Biological
Psychiatry the Official Journal of the World Federation of Societies of Biological
Psychiatry, 10(1), 34-42.
Vanderhasselt, M. A., De Raedt, R., Baeken, C., Leyman, L., D’haenen, H. (2006). The
influence of rTMS over the left dorsolateral prefrontal cortex on Stroop task
performance. Experimental Brain Research, 169, 279-282.

80

Van Praag, H. M. (2001). Past expectations, present disappointments, future hopes or
psychopathology as the rate-limiting step of progress in psychopharmacology.
Human Psychopharmacology, 16, 3-8.
Wang, H., Xue, Y., Chen, Y., Zhang, R., Wang, H., Yahong, Z., Jingli, G., Zhang, L., &
Qingrong, T. (2013). Efficacy of repetitive transcranial magnetic stimulation in
the prevention of relapse of depression: study protocol for a randomized
controlled trial. PubMed Central
Wasserman, E. M. (1998). Risk and safety of repetitive transcranial magnetic stimulation:
report and suggested guidelines from the International Workshop on the Safety of
Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996.
Electroencephalography and Clinical Neurophysiology 108, 1-16.
Weiland-Fiedler, P., Erickson, K., Waldeck, T., Luckenbaugh, D. A., Pike, D., Bonne,
O., Charney, D. S., & Neumeister, A. (2004). Evidence for continuing
neuropsychological impairments in depression. Journal of Affective Disorders,
82, 253-258.
World Health Organization, 2001. The World Health Report 2001. Mental Health: New
Understanding, New Hope. World Health Organization, Geneva.
Wurtman, R. J. (2005). Genes, stress, and depression. Metabolism, 54, 16-19.
Young, E. A., Haskett, R. F., Murphy-Weinburg, V., Watson, S. J., Akil, H. (1991). Loss
of glucocorticoid fast feedback in depression. Archives of General Psychiatry, 48,
693-699.

81

VITA
ALEXIS J. CHAPPELL
Virginia Consortium Program in Clinical Psychology
Norfolk State University, 700 Park Ave. /MCAR 410
Norfolk, VA 23504● chappea@evms.edu
EDUCATION
2016

2005 – 2007
1997 – 2001

Virginia Consortium Program in Clinical Psychology
Norfolk, Virginia
Ph.D., expected August, 2016
University-based, APA accredited program, jointly sponsored by:
Eastern Virginia Medical School, Norfolk State University, and
Old Dominion University
College of William and Mary
Williamsburg, Virginia
M.Ed., Community and Addictions Counseling, magna cum laude
James Madison University
Harrisonburg, Virginia
B.S., Psychology, minor in Substance Abuse Intervention

PRE-DOCTORAL CLINICAL PSYCHOLOGY INTERNSHIP:
2015 – 16

Eastern Virginia Medical School – Dept. of Psychiatry and Behavioral Sciences
Norfolk, Virginia
Physical Med. & Rehabilitation (Major Rotation), Sentara Norfolk General Hospital
Adult and Pediatric Neuropsychology (Minor Rotation), EVMS Neuropsychology
Organ Transplant Evaluation (Adjunct Clinical Experience), Sentara Heart Hospital
Outpatient Clinic (Minor Rotation), EVMS Dept. of Psychiatry and Behavioral
Sciences.
Consultation and Liaison Service (Major Rotation), Sentara Norfolk General Hospital

PRESENTATIONS
Chappell, A., Neumann, S.A., Sayegh, P.A., Seagly, K., Bayan, S. (2014, November). Neurocognitive
Performance as a Function of Right-Sided, Low-Frequency rTMS Administration in Treatment
Resistant Depression. Poster presented at the National Academy of Neuropsychology Annual
Convention, Fajardo, Puerto Rico.
Chappell, A., Estes, B., Winstead, B. (2013, October). Levels of Functional Independence and
Performance on Embedded Measures of Effort. Poster presented at the National Academy of
Neuropsychology Annual Convention, San Diego, California.
Chappell, A. (2014, October). Levels of Functional Independence and Performance on Embedded
Measures of Effort. Presented at the Virginia Consortium Program in Clinical Psychology Annual
Research Day.
Banks, G., Chappell, A. (2006, May). Comprehensive, Community-Wide Substance Abuse Needs
Assessment. Presented at the Historic Triangle Substance Abuse Coalition Annual Convention,
Williamsburg, Virginia.

